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PURPOSE AND SCOPE OF THE GUIDANCE 
This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 
Practice Guidelines for Treatment of Chronic Hepatitis B (1) and update the previous 
hepatitis B virus (HBV) guidelines from 2009.  The 2018 updated guidance on chronic 
hepatitis B (CHB) includes (i) updates on treatment since the 2016 HBV guideline 
(notably the use of tenofovir alafenamide) and guidance on (ii) screening, counseling, 
and prevention; (iii) specialized virologic and serologic tests; (iv) monitoring of untreated 
patients; and (v) treatment of hepatitis B in special populations, including persons with 
viral coinfections, acute hepatitis B, recipients of immunosuppressive therapy, and 
transplant recipients.  
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The AASLD 2018 Hepatitis B Guidance provides a data-supported approach to 
screening, prevention, diagnosis, and clinical management of patients with hepatitis B.  It 
differs from the published 2016 AASLD guideline which conducted systematic reviews 
and used a multidisciplinary panel of experts to rate the quality (level) of the evidence 
and the strength of each recommendation using the Grading of Recommendations 
Assessment, Development and Evaluation system in support of guideline 
recommendations (1–4). In contrast, this guidance document was developed by 
consensus of an expert panel, without formal systematic review or use of the Grading of 
Recommendations Assessment, Development, and Evaluation system. The 2018 
guidance is based upon the following: (i) formal review and analysis of published 
literature on the topics; (ii) World Health Organization guidance on prevention, care, and 
treatment of persons with CHB (5); and (iii) the authors’ experience in acute hepatitis B 
and CHB.  
 
Intended for use by health care providers, this guidance identifies preferred approaches 
to the diagnostic, therapeutic, and preventive aspects of care for patients with CHB. As 
with clinical practice guidelines, it provides general guidance to optimize the care of the 
majority of patients and should not replace clinical judgement for a unique patient. This 
guidance does not seek to dictate a “one size fits all” approach for the management of 
CHB. Clinical considerations may justify a course of action that differs from this 
guidance. 
 
Interim Data Relevant to the AASLD 2018 Hepatitis B Guidance 
 
Since the publication of the 2016 AASLD Hepatitis B Guideline, tenofovir alafenamide 
(TAF) has been approved for treatment of CHB in adults. Tenofovir alafenamide joins 
the list of preferred HBV therapies, along with entecavir, tenofovir disoproxil fumarate 
(TDF), and peginterferon (peg-IFN) (Tables 1 and 2) (6–16) (section: UPDATED 
RECOMMENDATIONS ON THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B).  
to TDF being elevated to the level of preferred therapy in this setting (section 1C of 
SCREENING, COUNSELING, AND PREVENTION OF HEPATITIS B).  
 
Tenofovir alafenamide, like TDF, is a nucleotide analogue that inhibits reverse 
transcription of pregenomic RNA to HBV DNA. Tenofovir alafenomide is more stable 
than TDF in plasma and delivers the active metabolite to hepatocytes more efficiently, 
allowing a lower dose to be used with similar antiviral activity, less systemic exposure, 
and thus decreased renal and bone toxicity.  
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The phase 3 trial of 873 hepatitis B e antigen (HBeAg)-positive patients (26% with prior 
nucleos(t)ide analogue [NA] therapy) randomized to TAF 25 mg daily or TDF 300 mg 
daily in a 2:1 ratio found similar 48-week responses, with serum HBV DNA <29 IU/mL in 
64% vs 67%, alanine aminotransferase (ALT) normalization in 72% vs 67%, HBeAg loss 
in 14% vs 12%, and hepatitis B surface antigen (HBsAg) loss in 1% vs 0.3% in the TAF 
and TDF groups, respectively (17). Week 96 follow-up results likewise showed that 73% 
and 75% had serum HBV DNA <29 IU/mL, 22% and 18% lost HBeAg, and 1% and 1% 
lost HBsAg in TAF and TDF patients, respectively (6).  
 
Analogously, a phase 3 trial of 426 HBeAg-negative patients (21% with prior NA therapy) 
randomized to TAF 25 mg daily or TDF 300 mg daily in a 2:1 ratio found comparable 48-
normalization in 83% vs 75% in the TAF and TDF groups, respectively. However, no 
patient in either group lost HBsAg (18). Week 96 follow-up results also showed serum 
HBV DNA <29 IU/mL in 90% of TAF patients and 91% of TDF patients, with 1 TAF-
treated patient losing HBsAg (7). The approved dose of TAF is 25 mg orally once daily, 
with no dose adjustment needed unless creatinine clearance is <15 mL/min.   
 
In these phase 3 studies, TAF had significantly less decline than TDF in bone density 
and renal function at 48 weeks of treatment. In HBeAg-positive patients, the mean 
decline in the estimated glomerular filtration rate was –0.6 mL/min for TAF patients, 
whereas the decline  was –5.4 mL/min in TDF patients (P < .0001). In HBeAg-negative 
patients, the mean  decline in the estimated glomerular filtration rate was –1.8 mL/min in 
TAF patients, whereas the decline for TDF patients was –4.8 mL/min (P = .004) (17, 18). 
In hip and spine bone mineral density measurements, the adjusted percentage 
difference in spine bone mineral density for TAF vs TDF was 1.88% (95% confidence 
interval 1.44 to 2.31, P < .0001) for HBeAg-positive patients and 1.64% (95% confidence 
interval 1.01 to 2.27, P < .0001) in HBeAg-negative patients (17, 18). In human 
immunodeficiency virus (HIV)–infected patients, TAF (N = 300) vs TDF (N = 333) 
containing antiretroviral therapy (ARVT) for up to 144 weeks also showed that TAF had 
a less negative impact on bone mineral density and renal biomarkers, with fewer 
patients on TAF vs TDF developing proximal tubulopathy (0 vs 4) or requiring treatment 
discontinuation because of renal complications (0 vs 12, P < .001) (19). While longer-
term data in HBV-monoinfected patients are lacking, particularly with respect to the 
impact on clinical outcomes such as renal disease and fracture risk, the current safety 
profile of TAF combined with evidence of similar antiviral efficacy led to its inclusion 
among the preferred HBV therapies for those patients requiring treatment.  
 
Most studies of switching from TDF to TAF come from the HIV literature. In studies of up 
to 96 weeks, a switch to TAF vs continued TDF treatment (as part of an antiretroviral 
regimen) was associated with improvements in proteinuria, albuminuria, proximal renal 
tubular function (mostly within the first 24 weeks), and bone mineral density (20). 
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Collectively, these studies suggest TAF has a better safety profile than TDF and similar 
antiviral efficacy in studies of up to 2 years’ duration.  
 
1. SCREENING, COUNSELING, AND PREVENTION OF HEPATITIS B 
 
1A. Screening 
The presence of HBsAg establishes the diagnosis of hepatitis B. Chronic vs acute 
infection is defined by the presence of HBsAg for at least 6 months. The prevalence of 
HBsAg varies greatly across countries, with high prevalence of HBsAg-positive persons 
defined as ≥8%, intermediate as 2% to 7%, and low as <2% (21, 22). In developed 
countries, the prevalence is higher among those who immigrated from high- or 
intermediate-prevalence countries and in those with high-risk behaviors (22, 23). 
 
Hepatitis B virus is transmitted by perinatal, percutaneous, and sexual exposure and by 
close person-to-person contact (presumably by open cuts and sores, especially among 
children in hyperendemic areas) (24, 25). In most countries where HBV is endemic, 
perinatal transmission remains the most important cause of chronic infection. Perinatal 
transmission also occurs in nonendemic countries (including the United States), mostly 
in children of HBV-infected mothers who do not receive appropriate HBV 
immunoprophylaxis at birth. The majority of children and adults with CHB in the United 
States are immigrants, have immigrant parents, or became exposed through other close 
household contacts (26, 27). 
 
HBV can survive outside the body for prolonged periods (28). The risk of developing 
chronic HBV infection after acute exposure ranges from 90% in newborns of HBeAg-
positive mothers to 25% to 30% in infants and children under 5 to less than 5% in adults 
(29–33). In addition, immunosuppressed persons are more likely to develop chronic HBV 
infection after acute infection (34).  
 
Table 3 displays those at risk for CHB who should be screened for HBV infection and 
immunized if seronegative (23, 35, 36). HBsAg and antibody to hepatitis B surface 
antigen (anti-HBs) should be used for screening (Table 4). Alternatively, antibody to 
hepatitis B core antigen (anti-HBc) can be utilized for screening as long as those who 
test positive are further tested for both HBsAg and anti-HBs to differentiate current 
infection from previous HBV exposure. HBV vaccination does not lead to anti-HBc 
positivity.  
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Some persons may test positive for anti-HBc but not HBsAg; they may or may not also 
have anti-HBs, with the prevalence depending on local endemicity or the risk group (37, 
38). The finding of isolated anti-HBc (anti-HBc positive but negative for HBsAg and anti-
HBs) can occur for a variety of reasons.  
(i) Among intermediate- to high-risk populations, the most common reason is 
previous exposure to HBV infection; the majority of these persons recovered 
from acute HBV infection earlier in life and anti-HBs titers have waned to 
undetectable levels, but some had been chronically infected with HBV for 
decades before clearing HBsAg. In the former case, the risk of hepatocellular 
carcinoma (HCC) or cirrhosis due to HBV is minimal. In the latter, these persons 
are still at risk of developing HCC, with an incidence rate that appears to be 
similar to those with inactive chronic HBV with undetectable HBV DNA levels 
(39–41). These individuals usually have low HBV DNA levels (20–200 IU/mL, 
more commonly if they are anti-HBs negative than if they are anti-HBs positive) 
and are typically born in regions with high prevalence of HBV infection or have 
HIV or hepatitis C virus (HCV) infection (37, 42–44).  
(ii) Much less commonly with new, more specific anti-HBc tests, anti-HBc may be a 
false-positive test result, particularly in persons from low-prevalence areas with 
no risk factors for HBV infection. Earlier anti-HBc enzyme immunoassay and 
radioimmunoassay tests were less specific, more frequently yielding false 
positive results (45).  
(iii) Anti-HBc may be the only marker of HBV infection during the window phase of 
acute hepatitis B; these persons should test positive for anti-HBc 
immunoglobulin M (37, 38).  
(iv) Lastly, reports exist of HBsAg mutations leading to false-negative HBsAg results 
(37).   
 
Because of the risk for HBV transmission, screening for anti-HBc occurs routinely in 
blood donors  and, if feasible, in organ donors (37). Since the original anti-HBc studies, 
the specificity of anti-HBc tests has improved to 99.88% in blood donors and 96.85% in 
non-HBV medical conditions (46, 47). Individuals with HIV infection or those about to 
undergo HCV or immunosuppressive therapy are at risk for potential reactivation if they 
have preexisting HBV and should be screened for anti-HBc (37, 48).  
 
The majority of individuals positive for anti-HBc do not have detectable HBV DNA (37), 
especially with older, less sensitive assays. For anti-HBc–positive individuals, additional 
tests to detect prior or current infection include immunoglobulin M anti-HBc, antibody to 
hepatitis B e antigen (anti-HBe), and HBV DNA with a sensitive assay. Detectable HBV 
DNA documents infectivity, but a negative HBV DNA result does not rule out low levels 
of HBV DNA. Additionally repeat anti-HBc testing can be performed over time, 
particularly in blood donors in whom subsequent anti-HBc negativity suggests an initial 
false-positive result (37, 48). Although reports vary depending on the sensitivity and 
specificity of the anti-HBc test used and HBV prevalence in the study population, the 
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minority of patients have an anamnestic response to HBV vaccination, with the majority 
having a primary antibody response to hepatitis B vaccination similar to persons without 
any HBV seromarkers (23, 49). Thus, vaccination could be considered reasonable for all 
screening indications in Table 3. Anti-HBc–positive HIV-infected individuals should 
receive HBV vaccination (ideally when CD4 counts exceed 200/µL) because most have 
primary responses to HBV vaccination, with ~60% to 80% developing anti-HBs levels 
≥10 mIU/mL after 3 or 4 vaccinations (50, 51). Thus, limited data suggest that 
vaccination may be considered (48, 52, 53). When considering the benefit of using an 
anti-HBc–positive donor organ with possible occult HBV infection, the harm of hepatitis B 
transmission must be weighed against the clinical condition of the recipient patient. 
 
While persons who are positive for anti-HBc but negative for HBsAg are at very low risk 
of HBV reactivation, the risk can be substantial when chemotherapeutic or 
immunosuppressive drugs are administered singly or in combination (see SCREENING, 
COUNSELING, AND PREVENTION OF HEPATITIS B, section 6D). Thus, all persons who are 
positive for anti-HBc (with or without anti-HBs) should be considered potentially at risk 
for HBV reactivation in this setting. 
 
Guidance Statements on Screening for Hepatitis B Infection 
1. Screening should be performed using both HBsAg and anti-HBs.   
2. Screening is recommended in all persons born in countries with a HBsAg 
seroprevalence of ≥2%, US-born persons not vaccinated as infants whose parents 
were born in regions with high HBV endemicity (≥8%), pregnant women, persons 
needing immunosuppressive therapy, and the at-risk groups listed in Table 3. 
3. Anti-HBs–negative screened persons should be vaccinated. 
4. Screening for anti-HBc to determine prior exposure is not routinely recommended but 
is an important test in patients who have HIV infection, who are about to undergo 
HCV or anticancer and other immunosuppressive therapies or renal dialysis, and in 
donated blood (or, if feasible, organs) (see SCREENING, COUNSELING, AND 
PREVENTION OF HEPATITIS B, section 6D).  
  
1B. Counseling Patients With Chronic Hepatitis B, Including Prevention of 
Transmission to Others 
 
Patients with chronic HBV infection should be counseled regarding lifestyle modifications 
and prevention of transmission as well as the importance of lifelong monitoring. No 
specific dietary measures have been shown to have any effect on the progression of 
CHB per se, but metabolic syndrome and fatty liver contribute to liver-related morbidity 
(54, 55).  Ingestion of more than 7 drinks per week for women and more than 14 drinks 
per week for men are associated with increased risk of cirrhosis and HCC (56, 57). 
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Studies evaluating the risk of lesser amounts of alcohol intake are sparse (58), but the 
conservative approach is to recommend abstinence or minimal alcohol ingestion (59, 
60). Individuals with CHB should be immunized against hepatitis A if not already immune 
(61).  
  
HBsAg-positive persons should be counseled regarding transmission to others (see 
Table 5). Because of increased risk of acquiring HBV infection, household members and 
sexual partners should be vaccinated if they test negative for HBV serologic markers. 
For casual sex partners or steady partners who have not been tested or have not 
completed the full immunization series, barrier protection methods should be employed. 
Transmission of HBV from infected health care workers to patients has been shown to 
occur in rare instances (62). For persons with CHB who are health care workers, the 
Centers for Disease Control and Prevention recommends that those who perform 
exposure-prone procedures should seek counseling and advice from an expert review 
panel (63).  If serum HBV DNA exceeds 1,000 IU/mL, antiviral therapy is recommended, 
and performance of exposure-prone procedures is permitted if serum HBV DNA is 
suppressed to <1,000 IU/mL and maintained below that cutoff (63). Since 2013, the US 
Department of Justice has ruled that it is unlawful for medical and dental schools to 
exclude applicants who are HBsAg positive. No special arrangements need to be made 
for HBV-infected children in the community other than practicing universal precautions in 
daycare centers, schools, sports clubs, and camps.  
 
Guidance Statements on Counseling of Persons Who Are HBsAg Positive  
1) HBsAg-positive persons should be counseled regarding prevention of transmission 
of HBV to others (Table 4). 
2) For health care workers and students who are HBsAg positive: 
a) They should not be excluded from training or practice because they have 
hepatitis B. 
b) Only HBsAg-positive health care workers and students whose job requires 
performance of exposure-prone procedures are recommended to seek 
counseling and advice from an expert review panel at their institution. They 
should not perform exposure-prone procedures if their serum HBV DNA level 
exceeds 1,000 IU/mL but may resume these procedures if their HBV DNA level is 
reduced and maintained below 1,000 IU/mL. 
3) No special arrangements are indicated for HBV-infected children in the community 
other than practicing universal precautions in daycare centers, schools, sports clubs, 
and camps.  
4) Abstinence or only limited use of alcohol is recommended in HBV-infected persons.  
5) Optimization of body weight and treatment of metabolic complications, including 
control of diabetes and dyslipidemia, are recommended to prevent concurrent 
development of metabolic syndrome and fatty liver. 
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Guidance Statements on Counseling of Persons Who Are HBsAg Negative and 
anti-HBc Positive (With or Without anti-HBs) 
1. Screening for anti-HBc is not routinely recommended except in patients who have 
HIV infection or who are about to undergo HCV therapy or immunosuppressive 
treatment.  
2. Persons who are anti-HBc positive without HBsAg are not at risk of transmission of 
HBV, either sexually or to close personal contacts. 
3. Persons who are positive only for anti-HBc and who are from an area with low 
endemicity with no risk factors for HBV should be given the full series of hepatitis B 
vaccine. 
4. Persons who are positive only for anti-HBc and have risk factors for hepatitis B 
(Table 3) are not recommended for vaccination unless they are HIV positive or 
immunocompromised. 
 
1C. Counseling of HBsAg-Positive Women in Pregnancy and Postpartum 
 
All pregnant women should be screened for HBsAg. Pregnant women with CHB should 
be encouraged to discuss with their obstetrician and/or pediatrician the prevention of 
mother-to-child transmission. Hepatitis B immune globulin (HBIG) and HBV vaccine 
should be administered to their newborn immediately after delivery (64). Antiviral therapy 
in the third trimester is recommended for pregnant women with serum HBV DNA 
>200,000 IU/mL (1, 4). 
 
A proportion of women (about 25%) have hepatitis flares with or without HBeAg 
seroconversion within the first months after delivery (65). Seroconversion rates of up to 
17% have been described.  It has been postulated that the rapid decrease in cortisol 
levels characteristic of the postpartum state is analogous to the steroid withdrawal 
therapy that has been used to elicit seroconversion. Although the flares are often mild 
and resolve spontaneously, cases of acute liver failure have been described in the 
peripartum period (66–68) . Extending third trimester antiviral therapy from 2 to 12 
weeks postpartum did not protect against postpartum flares in one study (68), supporting 
the AASLD guideline recommendation that antiviral therapy given for prevention of 
mother-to-child transmission be discontinued at the time of delivery or up to 4 weeks 
postpartum (1).   
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Prior systematic review of any antiviral therapy in the third trimester showed a 
significant reduction in perinatal transmission of HBV (4) with lamivudine, 
telbivudine, or TDF, but TDF is the preferred choice owing to its antiviral potency 
and concerns for resistance with the other antiviral agents. Two recent 
randomized control trials of TDF vs no antiviral treatment in the third trimester 
confirmed significant reductions in risk of mother-to-child transmission of hepatitis 
B with TDF in women with a high level of HBV DNA (69, 70). Elevated maternal 
creatine kinase levels were more frequent in TDF-treated vs untreated women in 
one study, though none were assessed as clinically significant (69). Both studies 
found no difference in the rates of prematurity, congenital malformations, or 
Apgar scores. Additional data on infant safety (including bone growth) from 
studies of pregnant women receiving antiretroviral therapy found no increase in 
adverse events among TDF-exposed vs unexposed infants (71–73). Although a 
prior study of HIV-infected pregnant mothers found TDF-exposed infants to have 
12% lower whole-body bone mineral content than unexposed infants (74), the 
follow-up study showed no differences at 2 years of age (71).  
 
Whether invasive procedures during pregnancy, such as amniocentesis, increase the 
risk of HBV infection in the infants is unclear. Two studies including 21 and 47 HBsAg 
mother-infant pairs respectively concluded that the risk of HBV transmission by 
amniocentesis is low (75). However, more recently, the risk of mother-to-child 
transmission of HBV was significantly higher in women with a high HBV DNA level (≥7 
log copies/mL) who underwent amniocentesis compared with those who did not (50% vs 
4.5%, odds ratio 21.3, 95% confidence interval 2.96 to 153) (75, 76). Therefore, the risk 
of mother-to-child transmission must be considered when assessing the potential benefit 
of amniocentesis in highly viremic women. 
 
Although antiviral drug labels do not recommend breastfeeding when taking these drugs, 
clinical studies support the safety of these drugs during breastfeeding (77, 78).  
 
Vaccination against HBV is both safe and efficacious during pregnancy (79).  In addition, 
titers of the passively transferred maternal antibody to newborns wane over time, as 
would be expected without the addition of active vaccination (80).  An accelerated 
vaccination schedule has been shown to be feasible and efficacious in high-risk 
pregnant women (81). Chronic HBV infection does not usually affect the outcome of 
pregnancy unless the mother has cirrhosis or advanced liver disease. However, extra 
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care is necessary to evaluate the mother and to ensure that the infant receives hepatitis 
B immune globulin and a birth dose of HBV vaccine.  
 
Guidance Statements on Counseling of Women in Pregnancy 
1. HBV vaccination is safe in pregnancy, and pregnant women who are not immune to 
or infected with HBV should receive this vaccine series.  
2. Women identified as HBsAg positive during pregnancy should be linked to care for 
additional testing (ALT, HBV DNA, imaging for HCC surveillance if indicated) and 
determination of need for antiviral therapy. 
3. Women who meet standard indications for HBV therapy should be treated.  Women 
without standard indications but who have HBV DNA >200,000 IU/mL in the second 
trimester should consider treatment to prevent mother-to-child transmission (1).  
4. HBV-infected pregnant women who are not on antiviral therapy as well as those who 
stop antiviral at or early after delivery should be monitored closely for up to 6 months 
after delivery for hepatitis flares and seroconversion. Long-term follow up should be 
continued to assess need for future therapy.  
5. The potential risk of mother-to-child transmission of HBV with amniocentesis should 
be included in the risk of harms vs benefits discussion in HBsAg-positive mothers 
with high level viremia. 
6. HBV-infected pregnant women with cirrhosis should be managed in high-risk 
obstetrical practices and treated with TDF to prevent decompensation. 
7. Sexual partners of women identified as HBV-infected during pregnancy should be 
assessed for HBV infection or immunity and receive HBV vaccine if appropriate. 
8. Breastfeeding is not prohibited. 
 
1D. Vaccination, Follow-up Testing, and Boosters 
Recommendations for vaccination are outlined in the Centers for Disease Control and 
Prevention and Advisory Committee on Immunization Practices guidelines (35, 82). 
Follow-up testing is recommended for those who remain at risk of infection, such as 
health care workers, infants of HBsAg-positive mothers, sexual partners of persons with 
CHB, chronic hemodialysis patients, and immunocompromised persons, including those 
with HIV. Furthermore, annual testing of hemodialysis patients is recommended since 
immunity wanes rapidly in these individuals who are at a high risk of continued exposure 
to HBV. Booster doses are not indicated in immunocompetent individuals if the primary 
vaccination series is completed, as long-term follow-up studies indicated that immune 
memory persists despite declining anti-HBs levels (83). For individuals undergoing 
postvaccination serologic testing, especially immunocompromised patients (such as 
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persons on dialysis or with chronic inflammatory conditions, including HIV), 
a booster injection is advised when the anti-HBs titer falls below 10 mIU/mL. 
 
For those who are nonresponders to the initial vaccination series, a second series of 0-, 
1-, and 6-month vaccination is recommended (84). For those who are 
immunocompromised, including those with HIV, on dialysis, or with cirrhosis, use of a 
double dose of vaccine has been shown to increase the percentage of patients 
achieving protective antibody titers, the level of anti-HBs achieved, and/or the duration of 
protection (85–87).  HBV vaccine with or without HBIG is also recommended for 
postexposure immunoprophylaxis of unimmunized individuals who have percutaneous, 
mucosal, or sexual exposure to HBsAg-positive or HBsAg-unknown sources. This 
includes bites, needlesticks, sexual contacts, and sexual assaults. Immunoprophylaxis 
should be administered within 24 hours of exposure. Studies are limited on the 
maximum interval after exposure during which postexposure prophylaxis is effective, but 
the interval is unlikely to exceed 7 days for percutaneous exposures and 14 days for 
sexual exposures. The Centers for Disease Control and Prevention has updated 
guidelines for vaccination and postexposure prophylaxis for health care workers (HCW) 
(88).  
 
Infants born to women whose HBsAg status is unknown should also receive prompt 
initiation of vaccination at birth. Because low-birth-weight infants (<2,000g) may have 
suboptimal vaccine responses, low-birth-weight infants of HBsAg-positive women should 
receive HBIG and HBV vaccine within 12 hours of birth followed by the usual 3-dose 
vaccination schedule, and premature or low-birth-weight infants born to HBsAg-negative 
women should be vaccinated prior to 1 month of age or at hospital discharge (89).  Only 
monovalent HBV vaccine should be used for preterm or term infants younger than 6 
weeks. 
 
Guidance Statements for Prevention of Transmission of Hepatitis B From 
Individuals With Chronic HBV Infection 
1. HBV vaccines have an excellent safety record and are given as a 3-dose series at 0, 
1, and 6 months (with or without hepatitis A vaccine). An alternate 4-dose schedule 
given at 0, 7, and 21 to 30 days followed by a dose at 12 months can be used for the 
combination hepatitis A and B vaccine (Twinrix®) for adults (90). Recently, a 2-dose 
series given at 0 and 1 months has been approved for adults (HEPLISAV-B®). 
2. Sexual and household contacts of HBV-infected persons who are negative for 
HBsAg and anti-HBs should receive HBV vaccination.  
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3. Newborns of HBV-infected mothers should receive HBIG and HBV vaccine at 
delivery and complete the recommended vaccination series.  Infants of HBsAg-
positive mothers should undergo postvaccination testing at 9 to 15 months of age. 
4. Health care workers, sexual partners of persons with chronic HBV infection, chronic 
hemodialysis patients, and immunocompromised persons (including those with HIV) 
should be tested for their response to the vaccination 1 to 2 months after the last 
dose of vaccine.  
5. For nonresponders to the initial vaccine series, a repeat 3-dose vaccination series is 
recommended, with a double dose used for immunocompromised patients, including 
those with cirrhosis (91). 
6. Follow-up testing of vaccine responders is recommended annually for chronic 
hemodialysis patients.  
7. Booster doses are not recommended except for individuals who are 
immunocompromised. 
 
2. DEFINITIONS AND PHASES OF CHRONIC HEPATITIS B INFECTION 
The diagnostic criteria for CHB and clinical terms relating to HBV infection are 
summarized in Table 6. The presence of HBsAg for at least 6 months establishes the 
chronicity of infection. As HBV is not directly cytopathic, host responses to the virus-
infected hepatocytes are believed to mediate liver cell injury and, with long-term chronic 
liver inflammation and ineffective immune-mediated viral clearance, contribute to the 
development of cirrhosis and liver cancer (92), (93). Importantly, CHB is a dynamic 
disease and individuals with CHB can transition through different clinical phases with 
variable levels of serum ALT activity, HBV DNA, and HBV antigens. The levels of serum 
ALT and HBV DNA as well as liver fibrosis are important predictors of long-term 
outcome that inform decisions for treatment initiation as well as treatment response. 
Therefore, serial testing of ALT and HBV DNA levels are needed to guide treatment 
decisions (Figure 1). Additionally, staging of liver disease severity using liver biopsy or 
noninvasive tests such as elastography are important in guiding surveillance and 
assisting with treatment decisions. 
 
The upper limits of normal (ULN) for ALT in healthy adults are reported to be 29 to 33 
U/L for males and 19 to 25 U/L for females (94–96). For purposes of guiding 
management of CHB, an upper limit of normal for ALT of 35 U/L for males and 25 U/L for 
females is recommended (Figure 1), though differences in repeat testing of the same 
sample have been described (97, 98). This might prompt clinicians to repeat testing 
when a single ALT elevation is near the cutoff for treatment. Interpretation of ALT 
elevations in the context of treatment decisions requires consideration that the ALT 
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elevation may be due to causes other than CHB, such as drug-induced liver injury, 
alcohol-associated liver disease, or fatty liver. 
 
3. SELECTED DIAGNOSTIC TESTS USED IN MANAGEMENT OF CHRONIC HEPATITIS B 
 
3A. HBV DNA Quantitation 
Quantification of serum HBV DNA is a crucial component in the evaluation of patients 
with CHB and in the assessment of the efficacy of antiviral treatment. Most HBV DNA 
assays used in clinical practice utilize real-time polymerase chain reaction technology 
with a sensitivity of 5 to 10 IU/mL and a dynamic range up to 7 log10 IU/mL (99). Some 
patients with CHB have widely fluctuating HBV DNA levels that may vary from 
undetectable to >2,000,000 IU/mL (100). Thus, serial monitoring of HBV DNA levels is 
more important than any single arbitrary cutoff value in prognostication and in 
determining the need for treatment. 
 
Generally, patients with inactive CHB have HBV DNA levels <2,000 IU/mL and those 
with immune-active CHB have HBV DNA levels >20,000 IU/mL, with levels lower in 
those with HBeAg-negative CHB than in HBeAg-positive CHB. The 20,000-IU/mL cutoff 
is an arbitrary value (101), which reflects the detection limit of historical non–polymerase 
chain reaction assays. However, chronic hepatitis, cirrhosis, and HCC have been found 
in patients with lower HBV DNA levels (102), highlighting the importance of interpreting 
HBV DNA levels in the context of other host factors (including age, duration of infection, 
ALT elevation, and stage of disease) when making treatment decisions (1).  
 
3B. HBV Genotypes 
Ten genotypes of HBV have been identified labeled A through J (103, 104) . The 
prevalence of HBV genotypes varies geographically. HBV genotypes A through H have 
been found in the United States, with genotypes A, B, and C being most prevalent (26).  
HBV genotypes may play an important role in the progression of HBV-related liver 
disease as well as response to interferon (IFN) therapy (103, 105). Genotype A (vs B–D) 
is associated with significantly higher rates of HBeAg and HBsAg loss with IFN therapy 
(105, 106). Studies from Asia found that HBV genotype B is associated with HBeAg 
seroconversion at an earlier age, more sustained remission after HBeAg 
seroconversion, less active hepatic necroinflammation, a slower rate of progression to 
cirrhosis, and a lower rate of HCC development compared with genotype C (103). 
Studies from Alaska also show that HBeAg seroconversion occurs on average 2 
decades later in persons infected with HBV genotype C than in those infected with HBV 
genotypes A, B, D, or F (107).  In addition, a significantly higher incidence of HCC has 
been reported in persons infected with genotypes C or F in Alaska compared with the 
others (108). 
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3C. Quantitative Hepatitis B Surface Antigen (qHBsAg) 
The desire to assess covalently closed circular DNA (cccDNA) inside hepatocytes led to 
development of reproducible, automated, and standardized (IU/mL) assays (Architect 
QT assay [Abbott], Elecsys HBsAg III Quant [Roche], Liaison XL [DiaSorin]) to quantify 
hepatitis B surface antigen (109). Although qHBsAg reflects covalently closed circular 
DNA and intrahepatic DNA levels, it also measures HBsAg that arises from integrated 
DNA, thereby reducing its specificity as a biomarker for viral replication. qHBsAg levels 
vary by genotype (higher in A) and by presence of preS/S mutants or host immune 
control (inverse correlation with both) (109). 
 
The levels of HBsAg are generally higher in HBeAg-positive patients than HBeAg-
negative patients (109–111). In HBeAg-negative patients, low qHBsAg (<1,000 IU/mL) 
and low HBV DNA (≤2,000 IU/mL) suggest inactive CHB. A qHBsAg <100 IU/mL 
increases the specificity of identifying those with inactive CHB but reduces sensitivity to 
35% (112). Higher qHBsAg levels have been associated with progression to cirrhosis 
and HCC. qHBsAg <1,000 IU/mL predicts spontaneous HBsAg clearance in HBeAg-
negative patients with a low viral load (113). 
 
For peg-IFN treatment of HBeAg-positive patients, qHBsAg helps predict response and 
provides a stopping rule. A qHBsAg <1500 IU/mL at week 12 resulted in likelihoods of 
57% for HBeAg seroconversion and 18% for HBsAg loss. Similarly, the absence of any 
decline at week 12 suggested that HBeAg loss or HBV DNA <2,000 IU/mL 24 weeks 
after treatment were unlikely (109). In particular, none of the patients with genotype B 
and C who had HBsAg >20,000 IU/mL at week 12 and 24 achieved HBeAg 
seroconversion (109). For peg-IFN treatment of HBeAg-negative patients, none of the 
genotype D patients who had no HBsAg decline and <2 log decline of HBV DNA at week 
12 had a treatment response, as defined by a sustained HBV DNA level <2,000 IU/mL 
off treatment (109). For NA treatment of HBeAg-negative patients, a >1 log decline in 
qHBsAg predicted increased loss of HBsAg, and qHBsAg level <100 IU/mL were 
associated with a sustainable off-treatment response following 3 years or more of 
consolidation therapy (109). 
 
3D. Viral Resistance Testing 
Hepatitis B antiviral drug resistance mutations in treatment-naïve patients are rare (114). 
For patients on antiviral therapy, the first manifestation of antiviral resistance is virologic 
breakthrough, which is defined as a 1 log10 (10-fold) increase in serum HBV DNA from 
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nadir during treatment in a patient who had an initial virologic response. Most antiviral-
resistant mutants have decreased replication fitness compared with wild-type HBV. 
However, compensatory mutations that can restore replication fitness frequently emerge 
during continued treatment, leading to a progressive increase in serum HBV DNA that 
may exceed pretreatment levels. Genotypic resistance, measured with commercially 
available assays, evaluate sequence variations in specific positions in the polymerase. 
The current diagnostic methods include restriction fragment length polymorphism 
analysis, hybridization, and sequencing (115). Current assays typically require an HBV 
DNA level >1,000 IU/mL.  
 
Guidance Statements on Use of Selected Serologic and Virologic Assays 
1. Quantitative HBV DNA testing is essential to guide treatment decisions, including 
initiation of treatment and evaluation of a patient’s response to antiviral treatment. 
2. HBsAg quantitation can be useful in managing patients receiving peg-IFN therapy. 
HBsAg quantitation is not recommended for the routine testing or follow-up of 
patients with CHB.  
3. HBV genotyping can be useful in patients being considered for peg-IFN therapy, as 
genotypes A and B are associated with higher rates of HBeAg and/or HBsAg loss 
than genotype C and D, but it is not otherwise recommended for routine testing or 
follow-up of patients with CHB. 
4. Testing for viral resistance in treatment-naïve patients is not recommended. 
Resistance testing can be useful in patients with prior treatment experience, those 
with persistent viremia on NA therapy, or those who experience virologic 
breakthrough during treatment.  
 
4. FOLLOW-UP OF PATIENTS NOT CURRENTLY ON ANTIVIRAL TREATMENT 
 
Patients not meeting criteria for antiviral therapy require regular monitoring to assess the 
need for future therapy per the AASLD 2016 HBV Guideline (1).  
 
4A. HBeAg-Positive Patients With High Serum HBV DNA but Normal ALT (Immune-
Tolerant CHB)  
These patients should be monitored at 3 to 6 month intervals (Figure 1). More frequent 
monitoring should be performed when ALT levels become elevated (116–119). Patients 
with compensated liver disease who remain HBeAg positive with HBV DNA levels 
greater than 20,000 IU/mL after a 3 to 6 month period of elevated ALT levels greater 
than 2 times the upper limit of normal (>50 U/L for women and >70 U/L for men) should 
be considered for antiviral treatment (1). Liver biopsy should be considered in patients 
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with persistent borderline normal or slightly elevated ALT levels, particularly in patients 
over age 40 who have been infected with HBV from a young age (120). Patients with 
moderate to severe inflammation (A3 or higher) and/or fibrosis (F2 or higher) can be 
considered for antiviral therapy (1). Noninvasive methods may be used in lieu of liver 
biopsies to assess for severity of fibrosis and/or inflammation (121, 122). Liver stiffness 
measurements are more accurate than serum fibrosis panels in predicting significant or 
advanced fibrosis (AST to platelet ratio index and FIB-4) (123, 124). Noninvasive 
methods overestimate fibrosis if high levels of necroinflammation, as reflected by 
elevated ALT, are present (122).  
 
4B. HBeAg-Negative, Anti-HBe–Positive Patients With Normal ALT and HBV DNA 
<2,000 IU/mL (Inactive CHB) 
These patients should be monitored with ALT determination every 3 months during the 
first year to verify that they are truly in the “inactive phase” and then every 6 to 12 
months (100, 125). If the ALT level becomes elevated, monitoring should occur more 
frequently. In addition, for persistent or recurrent ALT elevation, additional evaluation for 
causes (eg, HBV DNA tests) should be initiated (Figure 1). Studies suggest that a 1-time 
qHBsAg test combined with HBV DNA may help differentiate HBeAg-negative patients in 
the “grey zone,” in which HBV DNA or ALT levels are borderline between inactive CHB 
and immune-active, HBeAg-negative CHB (126, 127) (Figure 1). In one study, 
qHBsAg <1,000 IU/mL and HBV DNA <2,000 IU/mL differentiated inactive CHB from 
HBeAg-negative, immune-active CHB with a sensitivity and specificity of 71% and 85%, 
respectively (127), but more validation of the specific cutoff is needed.  
 
4C. Patients Who Have Achieved HBsAg Loss Spontaneously or With Therapy 
(Resolved CHB or Functional Cure) 
Spontaneous HBsAg loss has been reported to occur at the rate of roughly 1% per year, 
but this rare event does not occur at a linear rate (128, 129).  In a study of 1076 patients 
with CHB in Taiwan, cumulative probabilities of spontaneous HBsAg loss were 8.1% 
after 10 years and increased to 44.7% after 25 years (129). HBsAg loss can also occur 
in response to antiviral therapy, being more common with IFN than with NAs.  Although 
progression of liver disease to cirrhosis or hepatic decompensation generally stops when 
patients lose HBsAg unless other causes of liver injury are present (eg, heavy alcohol 
consumption or nonalcoholic fatty liver), the risk of HCC persists, particularly if HBsAg 
loss occurred in patients older than 50 years or in those with cirrhosis or coinfection with 
HCV or hepatitis D virus (HDV) (128, 130–132). Loss of HBsAg with acquisition of anti-
HBs has been termed functional cure. This is distinguished from true cure, in which 
HBsAg and covalently closed circular DNA are eliminated. 
 
Guidance Statements for Monitoring Patients With Chronic HBV Infection Who Are 
Not Currently on Treatment 
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1. As CHB is a dynamic disease, persons who are not receiving treatment should be 
assessed regularly to determine if an indication for treatment has developed. 
2. HBeAg-positive patients with persistently normal ALT should be tested for ALT at 3- 
to 6-month intervals. If ALT levels increase above upper limits of normal, ALT along 
with HBV DNA should be tested more frequently. HBeAg status should be checked 
every 6 to 12 months.  
3. Patients who are HBeAg positive with HBV DNA levels >20,000 IU/mL and ALT 
levels less than 2 times the ULN (<50 U/L for females, <70 U/L for males) should 
undergo testing to evaluate histologic disease severity, especially those >40 years 
old and who were infected at young age (ie, long duration of infection). 
 Liver biopsy offers the only means of assessing both fibrosis and inflammation. If 
the biopsy specimen shows moderate or severe inflammation (A2 or A3) or 
significant fibrosis (≥F2), treatment is recommended. 
 Alternative methods to assess fibrosis are elastography (preferred) and liver 
fibrosis biomarkers (eg, FIB-4 or FibroTest®). If these noninvasive tests indicate 
significant fibrosis (≥F2), treatment is recommended. 
4. Patients who are HBeAg negative with HBV DNA levels >2,000 IU/mL and elevated 
ALT levels less than 2 times the ULN should undergo testing to evaluate disease 
severity, especially those who are >40 years old and who were infected at a young 
age (ie, long duration of infection). 
 Liver biopsy offers the only means of assessing both fibrosis and inflammation. If 
the biopsy specimen shows moderate or severe inflammation (A2 or A3) or 
significant fibrosis (≥F2), treatment is recommended. 
 Alternative methods to assess fibrosis are elastography (preferred) and liver 
fibrosis markers (eg, FIB-4 or FibroTest®). If these noninvasive tests indicate 
significant fibrosis (≥F2), treatment is recommended. 
5. Patients who are HBeAg negative with normal ALT (≤25 U/L women, ≤35 U/L men) 
and HBV DNA <2,000 IU/mL should be tested for ALT and HBV DNA every 3 
months during the first year to confirm they have inactive CHB. Thereafter their ALT 
and HBV DNA levels should be tested at 6- to 12-month intervals. If costs are a 
concern, ALT monitoring alone can be used. When ALT levels increase above the 
normal limit, ALT along with HBV DNA should be tested more frequently (every 3–6 
months).  
6. In persons with HBV DNA <2,000 IU/mL but elevated ALT levels, other causes of 
liver disease should be investigated, including but not limited to HCV or HDV, drug 
toxicity, nonalcoholic fatty liver, alcohol, or autoimmune liver disease. 
7. Persons with inactive CHB should be evaluated for loss of HBsAg annually. 
8. In persons who achieve sustained HBsAg seroclearance, routine ALT and HBV DNA 
monitoring are no longer required.  HCC surveillance should continue if the person 
has cirrhosis, a first-degree family member with HCC, or a long duration of infection 
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(>40 years for males and >50 years for females who have been infected with HBV 
from a young age).   
  
5. SCREENING FOR HCC 
The AASLD 2018 Practice Guideline on HCC has been published (133).  Of the 2 tests 
prospectively evaluated as screening tools for HCC, alpha-fetoprotein (AFP) and 
ultrasonography (US), the sensitivity, specificity, and diagnostic accuracy of US are 
higher than those of AFP. The guideline for HCC recommends surveillance of persons at 
high risk of HCC with US every 6 months. There was insufficient evidence for or against 
the addition of AFP every 6 months to screening algorithms. AFP alone is not 
recommended except in those circumstances where US is unavailable or cost is an 
issue. HCC surveillance is considered cost-effective if the annual risk of HCC is ≥0.2% 
per year (134). Using this principle, all patients with cirrhosis warrant screening. For 
noncirrhotic patients, age, sex, race, and family history determine when surveillance 
should begin (134, 135). Other subgroups with a higher risk of HCC include persons with 
HCV, HDV, or HIV coinfections and those with fatty liver (55, 136–139). At this time, 
there is insufficient evidence to recommend HCC surveillance in children except in 
children with cirrhosis or with a first-degree family member with HCC.  
 
Guidance Statements for HCC Screening in HBsAg-Positive Persons 
1. All HBsAg-positive patients with cirrhosis should be screened with US examination 
with or without alpha-fetoprotein every 6 months. 
2. HBsAg-positive adults at high risk for HCC (including Asian or African American men 
over 40 years and Asian women over 50 years of age), persons with a first-degree 
family member with a history of HCC, or persons with HDV should be screened with 
US examination with or without alpha-fetoprotein every 6 months.  
3. There are insufficient data to identify high-risk groups for HCC in children. However, 
it is reasonable to screen HBsAg-positive children and adolescents with advanced 
fibrosis (F3) or cirrhosis and those with a first-degree family member with HCC using 
US examination with or without alpha-fetoprotein every 6 months. 
4. For HBsAg-positive persons at high risk for HCC who are living in areas where US is 
not readily available, screening with AFP every 6 months should be performed. 
 
6. MANAGEMENT OF CHRONIC HBV IN SPECIAL POPULATIONS 
 
6A. Coinfection With HCV 
As with any patient with CHB, the treatment goals are to reduce risk of progression to 
cirrhosis and liver-related complications, including HCC. In HBV-HCV coinfected 
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patients, the viral activity responsible for liver disease can be determined by measuring 
HCV RNA and HBV DNA levels. If HCV RNA is detectable, treatment of HCV should be 
undertaken (140). If HBV DNA is detectable, treatment is determined by the HBV DNA 
and ALT levels (Figure 1) (1). Importantly, treatment of one virus may lead to changes in 
the activity of the other virus, and thus monitoring during and after treatment is 
necessary to assess for viral activity.   
 
In the IFN era, the treatment of choice for patients coinfected with HBV and HCV 
infections was peg-IFN and ribavirin for 24 to 48 weeks, depending on the HCV 
genotype. Moderate to high rates of HCV eradication and HBV suppression were 
reported with this combination (141, 142). However, a rebound in serum HBV DNA after 
an initial decline and increased HBV replication in patients with undetectable HBV DNA 
prior to treatment have been reported with peg-IFN and ribavirin (141, 143, 144). 
Similarly, direct-acting antiviral (DAA) HCV therapy has been reported to increase HBV 
DNA levels in HBsAg-positive patients (145) and to elevate ALT concurrently with HBV 
reactivation, leading to liver decompensation (146), though the frequency of liver failure 
is very low (145, 147). The majority of reported reactivation events (elevated ALT with 
elevated HBV DNA) occurred between 4 to 12 weeks of DAA treatment (148).  
 
In those HBV-HCV coinfected patients with cirrhosis or those meeting recommended 
criteria for HBV treatment (Figure 1), HBV antiviral therapy should be started 
concurrently with DAA therapy (140). Entecavir, TDF, or TAF are the preferred antivirals. 
For HBsAg-negative, anti-HBc-positive patients with chronic HCV infection, monitoring 
ALT levels is reasonable, with testing for HBsAg and HBV DNA recommended if ALT 
levels fail to normalize or increase despite declining or undetectable HCV RNA levels. 
HBV antiviral therapy should be initiated if there is evidence of HBV reactivation 
(increase in HBV DNA from baseline—see section 6D1). There are no known 
interactions between HBV antivirals (entecavir, TDF, TAF) and approved HCV DAAs. 
For triply infected patients with HIV, HBV, and HCV, more opportunities for drug 
interactions exist, and careful review of antiretroviral therapy before initiation of HCV or 
HBV therapy is recommended (SCREENING, COUNSELING, AND PREVENTION OF HEPATITIS 
B, section 6C).  
 
Guidance Statements for Treatment of Patients with HBV and HCV Coinfection 
1. All HBsAg-positive patients should be tested for HCV infection using the anti-HCV 
test. 
2. HCV treatment is indicated for patients with HCV viremia (113). 
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3. HBV treatment is determined by HBV DNA and ALT levels as per the AASLD HBV 
guidelines for monoinfected patients (1).  
4. HBsAg-positive patients are at risk of HBV DNA and ALT flares with HCV DAA 
therapy, and monitoring of HBV DNA levels every 4 to 8 weeks during treatment and 
for 3 months posttreatment is indicated in those who do not meet treatment criteria 
for monoinfected patients (per AASLD–Infectious Diseases Society of America HCV 
Guidance). 
5. HBsAg-negative, anti-HBc positive patients with HCV are at very low risk of 
reactivation with HCV DAA therapy. ALT levels should be monitored at baseline, at 
the end of treatment, and during follow-up, with HBV DNA and HBsAg testing 
reserved for those whose ALT levels increase or fail to normalize during treatment or 
posttreatment.  
 
6B. Hepatitis D Infection 
The AASLD 2016 HBV Guideline recommends testing of HBsAg-positive persons at risk 
for HDV, including those with HIV infection, persons who inject drugs, men who have 
sex with men, and immigrants from areas of high HDV endemicity (149, 150) (Table 7) 
Additionally, HBsAg-positive patients with low or undetectable HBV DNA but high ALT 
levels should be considered for HDV testing. Given the importance of HDV to the long-
term management of the HBsAg-positive patient, if there is any uncertainty regarding the 
need to test, HDV screening is recommended. The recommended screening test is anti-
HDV, and if this test result is positive, it should be followed by HDV RNA testing to 
diagnose active HDV infection. A high degree of heterogeneity in sensitivity and 
specificity has been identified across HDV assays (151), and the availability of the first 
international external quality control for HDV quantification via the World Health 
Organization has led to improvements in HDV diagnostics. 
 
The primary endpoint of treatment is the suppression of HDV replication, which is usually 
accompanied by normalization of ALT levels and a decrease in necroinflammatory 
activity on a liver biopsy specimen. For patients with elevated ALT levels, measurement 
of HBV DNA and HDV RNA will allow determination of the need for NA alone, peg-IFN 
alone, or combination therapy. The presence of underlying cirrhosis may further modify 
treatment decisions, as is the case in HBV monotherapy. Because NAs have no efficacy 
against HDV infection, they are not recommended in patients with suppressed or low 
HBV replication except patients with cirrhosis. HBV DNA levels may change over time, 
including during treatment of HDV infection, and if the HBV DNA levels become 
elevated, treatment with preferred NAs (entecavir, TDF, TAF) is recommended. Long-
term suppression of active HBV infection may be expected to reduce quantitative HBsAg 
levels, which should have a beneficial effect on HDV coinfection. 
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The only approved treatment of chronic hepatitis D is IFN-α. Peg-IFN is the drug of 
choice without clear differences in efficacy between peg-IFN alpha-2a (180 µg weekly) 
or 2b (1.5 µg/kg weekly) (152). Treatment success, defined as undetectable HDV RNA 
24 weeks after completing treatment, ranges from 23% to 57% (152–154). ALT 
normalization typically parallels the virologic responses. The combination of NA with 
peg-IFN does not increase the likelihood of an off-treatment virologic response (153). 
Late relapses can occur with longer follow-up, leading to very low rates of sustained 
HDV RNA undetectability. In the multicenter HIDIT-1 study of peg-IFN for 48 weeks with 
or without adefovir, 40% of patients achieved an undetectable HDV RNA level 24 weeks 
after completing therapy (153), but at a mean follow-up 4.3 years later, only 12% 
remained undetectable (155). A complete virologic response, defined as loss of HBsAg 
plus sustained suppression of HDV RNA, is a more desirable endpoint of therapy, but 
this occurs rarely with 1 year of treatment. Longer treatment duration may increase 
HBsAg loss, eg, peg-IFN for up to 5 years resulted in HBsAg loss in 3 of 13 patients 
(23%) (156). 
 
An early virologic response, defined by loss of HDV RNA after 24 weeks of treatment, 
was associated with a higher likelihood of a sustained off-treatment response, whereas a 
failure to achieve at least a 2-log copies/mL decline by this same time point was 
associated with a <5% chance of sustained off-treatment response (157). The benefits of 
peg-IFN on disease progression and clinical outcomes have been most closely 
associated with undetectability of HDV RNA during follow-up. 
 
Given the poor response to current peg-IFN therapy, new drug therapies are urgently 
needed for HDV-infected persons. Phase 2 studies of prenylation inhibitors and entry 
inhibitors offer hope for new treatment options in the future (158, 159). 
 
Guidance Statements for Management of Patients With HDV Infection 
1. Anti-HDV screening is recommended in HIV-positive persons, persons who inject 
drugs, men who have sex with men, those at risk for sexually transmitted diseases, 
and immigrants from areas of high HDV endemicity. Patients with low HBV DNA 
levels and elevated ALT levels may be considered for HDV screening. If there is any 
uncertainty regarding the need to test, an initial anti-HDV test is recommended.  
2. For those at risk for HDV acquisition, periodic retesting is recommended.  
3. Anti-HDV–positive patients should have periodic assessment of HDV RNA and HBV 
DNA.  
4. Peg-IFN-α for 12 months is the recommended therapy for those with elevated HDV 
RNA levels and ALT elevation. 
5. If HBV DNA levels are elevated, concurrent therapy with NA using preferred drugs 
(entecavir, TDF, or TAF) is indicated. 
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6. Assessment of HDV relapse is warranted if ALT elevation occurs following treatment 
because of the high rates of relapse.  
7. Given the limited efficacy of current therapies, it is reasonable to refer patients to 
specialized centers that offer access to experimental therapies for HDV. 
 
6C. Coinfection With HIV 
Lamivudine, emtricitabine, and tenofovir are NAs with activity against both HIV and HBV 
(160, 161). However, the rate of HBV resistance to lamivudine monotherapy in HBV and 
HIV coinfected patients reaches 90% at 4 years (162). All patients with HBV and HIV 
coinfection should receive ARVT that includes 2 drugs with activity against HBV: 
specifically, tenofovir (TAF or TDF) plus lamivudine or emtricitabine (163). In the setting 
of confirmed lamivudine resistance in patients already receiving ARVT therapy, adding 
tenofovir is generally preferred. Tenofovir alafenamide is approved for HIV in 
combination with emtricitabine with or without other HIV drugs and is preferred to 
tenofovir disoproxil fumarate because of its improved safety profile (20, 164–166). 
 
Because entecavir has been shown to decrease serum HIV RNA levels in lamivudine-
experienced and lamivudine-naïve patients and result in the selection of M184V 
mutation (167), entecavir should only be used in HBV and HIV coinfected patients 
receiving a fully suppressive antiretroviral regimen (163).  Telbivudine and adefovir are 
not recommended (163) because adefovir has no activity against HIV and telbivudine 
results in the selection of M204I mutation in the YMDD motif. 
  
Hepatitis flares may occur during the first few weeks of treatment from immune 
reconstitution (168) or when drugs with HBV activity are discontinued, particularly in the 
absence of HBeAg seroconversion. Thus, when ARVT regimens are altered, drugs that 
are effective against HBV should not be discontinued without substituting another drug 
that has activity against HBV. Elevation in ALT can also be due to hepatotoxicity of HIV 
drugs or HIV-related opportunistic infections (169, 170). HBV treatment should be 
continued indefinitely with monitoring of virologic response and adverse events.  
 
Guidance Statements for Treatment of Patients With HBV and HIV Coinfection 
1. All patients with HBV and HIV coinfection should initiate ARVT, regardless of CD4 
count.  The ARVT regimen should include 2 drugs with activity against HBV. 
Specifically, the backbone of the ARVT regimen should be TDF or TAF plus 
lamivudine or emtricitabine. 
2. Patients who are already receiving effective ARVT that does not include a drug with 
antiviral activity against HBV should have treatment changed to include TDF or TAF 
with emtricitabine or lamivudine. Alternatively, entecavir is reasonable if patients are 
receiving a fully suppressive ARVT. 
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3. When ARVT regimens are altered, drugs that are effective against HBV should not 
be discontinued without substituting another drug that has activity against HBV. 
4. TDF-emtricitabine–inclusive regimens require dose adjustment if creatinine 
clearance is <50 mL/min, and TAF-emtricitabine–inclusive regimens are not 
recommended in patients with a creatinine clearance of <30 mL/min. 
 
 
6D. Patients Who Receive Immunosuppressive or Cytotoxic Therapy 
6D.1 Definitions for HBV Reactivation and Associated Outcomes 
HBV reactivation reflects the loss of HBV immune control in HBsAg-positive, anti-HBc–
positive or HBsAg-negative, anti-HBc–positive patients receiving immunosuppressive 
therapy for a concomitant medical condition. The criteria for HBV reactivation (171–178) 
include the following: (i) a rise in HBV DNA compared to baseline (or an absolute level of 
HBV DNA when a baseline is unavailable) and (ii) reverse seroconversion 
(seroreversion) from HBsAg negative to HBsAg positive for HBsAg-negative and anti-
HBc–positive patients. Following HBV reactivation, a hepatitis flare demonstrated by 
ALT elevation can occur.  Many previous studies were retrospective and thus lacked the 
data to fully describe the incidence of HBV-associated hepatitis, liver failure (manifested 
by impaired synthetic function, ascites, or encephalopathy), or liver-associated death. 
However, one systematic review reported liver failure rates among HBsAg-positive, anti-
HBc–positive patients receiving anticancer therapy to be 13.9% (pooled estimate: range 
8.6%–20.3%) (177). Because of the heterogeneity of definitions for HBV reactivation and 
its associated outcomes, we recommend using uniform criteria and propose coupling 
HBV reactivation with a hepatitis flare to define HBV-associated hepatitis. The AASLD-
recommended criteria for HBV-associated hepatitis and associated clinical outcomes are 
as follows:  
a. HBV-Associated Hepatitis (HBV Reactivation Plus Hepatitis Flare) 
HBV reactivation in HBsAg-positive, anti-HBc–positive patients is reasonably defined as 
1 of the following: (i) a ≥2 log (100-fold) increase in HBV DNA compared to the baseline 
level, (ii) HBV DNA ≥3 log (1,000) IU/mL in a patient with previously undetectable level 
(since HBV DNA levels fluctuate), or (iii) HBV DNA ≥4 log (10,000) IU/mL if the baseline 
level is not available. For HBsAg-negative, anti-HBc–positive patients, the following 
criteria are reasonable for HBV reactivation: (i) HBV DNA is detectable or (ii) reverse 
HBsAg seroconversion occurs (reappearance of HBsAg). A hepatitis flare is reasonably 
defined as an ALT increase to ≥3 times the baseline level and >100 U/L. 
b. Clinical Outcomes of HBV-Associated Hepatitis 
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HBV-associated liver failure is reasonably defined as 1 of the following: (i) 
impaired synthetic function (total bilirubin >3 mg/dL or international normalized 
ratio >1.5), (ii) ascites, (iii) encephalopathy, or (iv) death following HBV-
associated liver failure due to HBV reactivation.  
 
6D.2  Screening Recommendations in the Setting of Immunosuppressive or Cytotoxic 
Drugs 
Previous studies showed that HBV reactivation from anticancer therapies occurred in 
41% to 53% (179) of HBsAg-positive, anti-HBc–positive patients and 8% to 18% (180) of 
HBsAg-negative, anti-HBc–positive patients. The rate of HBV reactivation from 
antirheumatic therapies has been reported to be 12.3% (181) in HBsAg-positive, anti-
HBc–positive patients and 1.7% (182) in HBsAg-negative, anti-HBc–positive patients. As 
such, both the HBsAg and anti-HBc (total or immunoglobulin G) tests should be used for 
HBV screening. The role for anti-HBs in screening prior to immunosuppressive therapy 
has not yet been established. The presence of anti-HBs does not prevent HBV 
reactivation, but anti-HBs may be useful for detecting prior infection in HBsAg negative, 
anti-HBc positive patients, and in surveillance as the loss of anti-HBs may be a predictor 
of HBV reactivation (183–185). 
 
In regions of the world where HBV prevalence is moderate to high, universal HBV testing 
prior to the initiation of immunosuppressive therapy is recommended (186, 187). In the 
United States, some medical centers have established universal HBV testing procedures 
that are aligned with the CDC recommendation (23). Among patients with cancer, HBV 
testing rates based on risk factors have been reported to be low (19% to 55%) (188-
190), while the prevalence of HBV risk factors among patients with cancer may be high 
(191). This supports universal HBV testing as a reasonable option to reduce the risk of 
missing persons with HBV infection prior to the initiation of anticancer therapies, 
especially in centers where widespread, systematic, risk-based HBV testing does not 
occur.  
 
6D.3 Antiviral Prophylaxis vs On-Demand Therapy 
Although many immunosuppressive and immune-modulating drugs have been 
associated with HBV reactivation (192–194), it is difficult to discern the risk caused by 
specific drugs or drug regimens because of the lack of systemically collected data. 
HBsAg-positive patients are at high risk of HBV reactivation, especially if their HBV DNA 
levels are elevated (195, 196), and they should receive anti-HBV prophylaxis prior to the 
initiation of immunosuppressive or cytotoxic therapy, which is supported by 3 
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randomized controlled trials of HBsAg-positive, anti-HBc–positive patients receiving 
anticancer therapy (174, 179, 197).  
 
HBsAg-negative, anti-HBc–positive patients are at lower risk of HBV reactivation than 
HBsAg-positive patients, and depending on their clinical situation and feasibility of close 
monitoring, they could be initiated on anti-HBV prophylaxis or monitored with the intent 
of on-demand anti-HBV therapy initiation at the first sign of HBV reactivation. HBsAg-
negative, anti-HBc–positive patients with rheumatologic conditions receiving biologic 
therapies (198-200), inflammatory bowel disease treated with TNF inhibitors (201), and 
patients with psoriasis treated with biologics or conventional immunosuppressive 
therapies (202) were successfully monitored without anti-HBV prophylaxis. While 
HBsAg-negative, anti-HBc–positive lymphoma patients have been reported to have been 
successfully monitored with close, on-demand antiviral therapy while receiving rituximab 
(180, 203, 204) or conventional anticancer therapy (204) without adverse liver outcomes, 
we recommend that HBsAg-negative, anti-HBc–positive patients on drugs that target B 
lymphocytes such as rituximab be given prophylaxis.  
 
6D.4. Preferred Antivirals and Duration of Therapy 
Regardless of baseline serum HBV DNA level, prophylactic antiviral therapy should be 
administered to patients with CHB before (ie, most often in the literature, antivirals were 
given 7 days prior to) the onset of anticancer therapy or a finite course of 
immunosuppressive therapy (205). Because of their higher potency and high resistance 
barrier, prophylactic first-line NAs (eg, entecavir or tenofovir) should be preferred over 
other NAs, as multiple meta-analyses have demonstrated reduced reactivation, hepatitis, 
mortality, and anticancer therapy interruption (192, 205–207). When monitoring at-risk 
patients without prophylaxis, the preferred antivirals for on-demand treatment remain 
first-line preferred NAs, although the evidence base is far weaker (192). The most 
commonly studied and recommended duration of prophylactic antiviral therapy is 6 to 12 
months (205) after discontinuation of anticancer therapy or immunosuppression. 
Reactivation beyond 12 months has been reported, so further monitoring should be 
considered, particularly for patients who received anti-CD20 antibody therapy (208–210). 
Much less is known about the optimal duration of prophylaxis in patients receiving 
chronic immunosuppression, eg, transplantation and biologic therapy (182, 211–214). 
 
Guidance Statements for Patients Undergoing Immunosuppressive and Cytotoxic 
Therapy 
Page 25 of 87
Hepatology
Hepatology









t HBV Guidance 2018  
26 
Submitted for publication on January 11, 2018 
1. HBsAg and anti-HBc (total or immunoglobulin G) testing should be performed in all 
persons prior to initiation of any immunosuppressive, cytotoxic, or 
immunomodulatory therapy.  
2. HBsAg-positive, anti-HBc–positive patients should initiate anti-HBV prophylaxis 
before immunosuppressive or cytotoxic therapy.  
3. HBsAg-negative, anti-HBc–positive patients could be carefully monitored with ALT, 
HBV DNA, and HBsAg with the intent for on-demand therapy, except for patients 
receiving anti-CD20 antibody therapy (eg, rituximab) or undergoing stem cell 
transplantation, for whom anti-HBV prophylaxis is recommended. 
4. When indicated, anti-HBV prophylaxis should be initiated as soon as possible before 
or, at the latest, simultaneously with the onset of immunosuppressive therapy. Once 
started, anti-HBV prophylaxis should continue during immunosuppressive therapy 
and for at least 6 months (or for at least 12 months for patients receiving anti-CD20 
therapies) after completion of immunosuppressive therapy.  
5. Anti-HBV drugs with a high resistance barrier (entecavir, TDF, or TAF) should be 
preferred over low-barrier agents.  
6. For patients being monitored without prophylaxis, HBV DNA levels should be 
obtained every 1 to 3 months. Patients should be monitored for up to 12 months after 
cessation of anti-HBV therapy.  
 
6E. Symptomatic Acute Hepatitis B Infection 
Antiviral therapy is generally not necessary in patients with symptomatic acute 
hepatitis B because >95% of immunocompetent adults with acute hepatitis B 
recover spontaneously. Small case series with or without comparisons to 
historical untreated controls have reported that lamivudine improves survival in 
patients with severe infection or acute liver failure (215, 216). In the largest 
randomized controlled trial of lamivudine vs placebo, 71 patients with acute 
symptomatic acute hepatitis B were studied, with over half of the patients having 
severe acute hepatitis B as defined by 2 of the following 3 criteria: hepatic 
encephalopathy, serum bilirubin >10.0 mg/dL, or international normalized ratio 
>1.6 (217). Although the group treated with lamivudine had a significantly greater 
reduction of HBV DNA at week 4, there was no difference in the rate of 
biochemical improvement for all patients and in the subgroup with severe 
hepatitis. Nor did the rate of loss of HBsAg differ at month 12: 93.5% with 
lamivudine vs 96.7% with placebo. Other studies of smaller size were 
underpowered to assess for benefits (216, 218).  
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Despite the above lack of observed benefit, treating all patients with acute liver failure 
due to HBV using an NA may be reasonable given its safety and the ultimate need for 
liver transplantation in many of these patients, for whom lower HBV DNA levels are 
desirable to reduce the risk of recurrent hepatitis B after transplant. At the 2006 National 
Institutes of Health HBV Meeting, it was also proposed that patients with protracted, 
severe, acute hepatitis B (increase in international normalized ratio and deep jaundice 
persisting for >4 weeks) be treated (219). Entecavir, TAF, or TDF are preferred antivirals 
in this setting. IFN-α is contraindicated because of the risks of worsening hepatitis and 
the frequent adverse effects. 
 
Guidance Statements for Treatment of Patients With Acute Symptomatic Hepatitis 
B 
1. Antiviral treatment is indicated for only those patients with acute hepatitis B who 
have acute liver failure or who have a protracted, severe course, as indicated by total 
bilirubin >3 mg/dL (or direct bilirubin >1.5 mg/dL), international normalized ratio > 
1.5, encephalopathy, or ascites. 
2. Entecavir, TDF, or TAF are the preferred antiviral drugs. 
 Treatment should be continued until HBsAg clearance is confirmed or indefinitely in 
those who undergo liver transplantation. 
 Peg-IFN is contraindicated.  
3. For those diagnosed with CHB by failing to clear HBsAg after 6 to 12 months, 
ongoing management should follow the chronic HBV guideline (1). 
 
6F. Treatment of Patients With Virologic Failure on NA Therapy   
A major concern with long-term NA treatment is the selection of antiviral resistance 
mutations. The rate at which resistance variants are selected is related to the 
pretreatment serum HBV DNA level, rapidity of viral suppression, duration of treatment, 
prior exposure to NA therapies, and most importantly, the NA’s genetic barrier to drug 
resistance. Among the preferred NA therapies for CHB, entecavir, TDF, and TAF have 
very low rates of drug resistance in NA-naïve patients, and tenofovir (TDF or TAF) has 
very low rates of drug resistance in NA-experienced patients (17, 18, 220, 221). 
 
Virologic breakthroughs, defined as a >1 log10 (10-fold) increase in serum HBV DNA 
from nadir after initial virologic response, may be related to medication nonadherence, 
so adherence should be ascertained before testing for genotypic resistance (222). 
Virologic breakthrough is usually followed by biochemical breakthrough, defined as ALT 
elevation during treatment in a patient who had achieved an initial biochemical response. 
Emergence of antiviral resistance mutations can lead to negation of the initial response 
and in some cases hepatitis flares and hepatic decompensation. Antiviral resistance 
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mutations may also result in cross-resistance with other NAs, thus reducing future 
treatment options.  
 
Resistance to entecavir appears to occur through a 2-hit mechanism, with initial 
selection of the lamivudine resistance M204V or M204I mutation followed by amino acid 
substitutions at rtT184, rtS202, or rtM250. In vitro studies showed that the mutations at 
positions 184, 202, or 250 on their own have a minimal effect on susceptibility to 
entecavir, but susceptibility to entecavir is decreased by 10- to 250-fold when one of 
these mutations accompanies a M204V or M204I mutation and by >500-fold when 2 or 
more of them are present with a M204V or M204I mutation. Thus, although entecavir 
monotherapy has a low rate of drug resistance in NA-naïve patients (approximately 1% 
after 5 years of treatment) (223), it has a high rate of resistance in lamivudine-refractory 
patients (approximately 50% after 5 years of treatment) (223). Use of entecavir at high 
doses (1 mg vs 0.5 mg daily) reduces the rate of resistance but is inferior to combination 
therapy of lamivudine plus adefovir or tenofovir monotherapy (224–229). Resistance to 
tenofovir (at position rtA194T) was reported in 2 patients with HBV and HIV coinfection 
(230), but this finding has not been confirmed by other studies. In phase III clinical trials 
of TDF, there was no evidence of TDF resistance among 641 NA-naïve patients who 
received TDF for up to 8 years, and most cases of virologic breakthrough were attributed 
to nonadherence (221). Similarly, in another study of 280 patients with lamivudine 
resistance who received TDF alone or in combination with emtricitabine for up to 240 
weeks, TDF resistance was not found (231). Although long-term data on risk of 
resistance with TAF are lacking, no resistance has been reported in clinical trials with 2-
year follow-up (6, 221).  
 
To prevent emergence of resistance, NAs with the lowest rate of genotypic resistance 
should be administered and adherence reinforced in treatment-naïve patients. De novo 
combination therapy is unnecessary when NAs with a high barrier to resistance 
(entecavir, TDF, or TAF) are used. Tenofovir disoproxil fumarate monotherapy has been 
shown to be effective in patients with lamivudine-, adefovir-, or entecavir- resistant HBV 
(231–233) and is the preferred salvage therapy, particularly in patients in whom the 
history of prior NA therapy is unclear (Table 8). Entecavir may be used in patients with 
adefovir or tenofovir-resistant HBV, though confirmed cases of tenofovir resistance are 
notably extremely rare (Table 8). Entecavir should not be used in patients with 
lamivudine or telbivudine resistance, as the risk of subsequent entecavir resistance is 
high. In vitro studies showed that susceptibility of adefovir-resistant HBV with a single 
N236T, A181V/T mutation to TDF is minimally changed compared with wild-type HBV, 
but susceptibility is lower when both mutations are present. Clinically, most studies have 
found that TDF is effective in suppressing adefovir-resistant HBV without any additional 
benefit from emtricitabine (231–233).  
 
Guidance Statements for Management of Persons With Persistent Low-
Level Viremia on NA Therapy (See UPDATED RECOMMENDATIONS ON THE 
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B, Section 6B) 
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6G. Decompensated Cirrhosis 
Patients with decompensated cirrhosis should be referred for consideration of liver 
transplantation. Concurrently, antiviral therapy should be started. Antiviral therapy has 
been shown to improve outcomes in decompensated cirrhosis, especially with early 
treatment initiation (234). Both improved liver function and increased survival have been 
reported in recent meta-analyses (2, 234, 235). Transplant-free survival has been shown 
to exceed 80% in patients who have been treated (2, 235, 236), with 1 study removing 
34% of treated patients from the liver transplantation waiting list (234). Survival 
depended on antiviral response and was significantly better in responders (234). 
Indefinite therapy is recommended in those with decompensated cirrhosis (1). Despite 
successful treatment with antivirals, this group remains at high risk for HCC and should 
continue long-term HCC surveillance (237–239). 
 
Peg-IFN is contraindicated in this patient group because of safety concerns (240). 
Entecavir or TDF are recommended as preferred first-line agents in patients with 
decompensated cirrhosis (1). Both have been shown to be effective and well tolerated 
(241–247). Tenofovir alafenamide  has not been studied in patients with decompensated 
cirrhosis, but use of TAF would be reasonable in patients when TDF adverse effects are 
a concern and entecavir is not an option. Among 112 patients with decompensated 
cirrhosis randomized to TDF, TDF with emtricitabine, or entecavir, the proportion with 
HBV DNA <69 IU/mL and normal ALT was similar at 48 weeks in all 3 groups (248). In a 
prospective study of 70 entecavir-treated patients with decompensated cirrhosis, the 1-
year transplant-free survival was 87.1%, with improved Model for End-Stage Liver 
Disease and Child-Turcotte-Pugh scores (236). In a prospective study of 96 patients, 
TDF treatment for 24 months significantly improved hepatic function and reversed 
decompensation (233), and in a prospective study of 57 patients with decompensated 
cirrhosis treated with TDF for 12 months, 49% improved their Child-Turcotte-Pugh score 
by 2 points (249). In this study, confirmed 0.5-mg/dL increases in creatinine occurred in 
7% of decompensated patients and 2.5% of compensated patients. In another 
retrospective study that included 52 patients with decompensated cirrhosis, TDF was 
shown to have similar renal safety to that of ETV over a 2-year period of time (250). 
 
Despite an overall high safety profile, lactic acidosis remains a rare but serious side 
effect with use of any NA and is likely a higher risk in patients with decompensated 
cirrhosis. In a single-center series, 5 of 16 patients with decompensated cirrhosis and 
Model for End-Stage Liver Disease scores ≥20 developed lactic acidosis (251). One 
case was fatal, and the other cases resolved after discontinuing antiviral therapy. No 
patient with a Model for End-Stage Liver Disease score below 18 developed lactic 
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acidosis in this study. For this reason, close monitoring of patients with decompensated 
cirrhosis receiving antiviral therapy is advised regardless of Model for End-Stage Liver 
Disease score. 
 
Guidance Statements for Patients With Decompensated Cirrhosis (See UPDATED 
RECOMMENDATIONS ON THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B, 
Section 7B) 
 
6H. Liver Transplant Recipients 
The prevention of HBV reinfection by using antiviral therapy pretransplant and continuing 
antiviral therapy with or without HBIG posttransplant has reduced the HBV reinfection 
rate to less than 10% (252). Antiviral therapy should be started in all patients with 
decompensated cirrhosis and detectable serum HBV DNA. Entecavir, TDF, and TAF are 
preferred antivirals because of their high potency and low rate of drug resistance. 
Although TAF is not FDA-approved for use in patients with decompensated cirrhosis, it is 
a reasonable option for patients needing tenofovir therapy (eg, patients who are 
lamivudine resistant) who have or are at risk for bone or renal diseases that might be 
complicated by the use of TDF.  Therapy should be continued posttransplant indefinitely, 
regardless of HBeAg or HBV DNA status. 
 
While many transplant centers use HBIG in addition to NAs during the early 
posttransplant period, transplant centers vary in the dose and duration of HBIG beyond 
the immediate posttransplant period. In patients at low risk for recurrence, either no 
HBIG or HBIG for only 5 to 7 days combined with NAs long-term has been highly 
effective (253, 254). In 42 consecutive HBsAg-positive patients with HBV DNA levels 
<100 IU/mL at the time of transplant, prophylaxis using HBIG (5,000 IU daily) in the 
anhepatic phase and for 5 days postoperatively in conjunction with long-term NA therapy 
prevented HBV recurrence in 97% at 3 years, with the only treatment failure being a 
patient with recurrent HCC (HBsAg detectable but HBV DNA undetectable) (210). The 
Hong Kong group has shown that HBIG-free prophylaxis using entecavir alone can 
prevent HBV recurrence (defined by HBsAg positivity) in the majority of patients. In 
265 recipients treated with entecavir monotherapy post–liver transplant, 85%, 88%, 
87%, and 92% remained HBsAg negative after 1, 3, 5, and 8 years of follow-up, 
respectively, and 100% maintained undetectable HBV DNA (255). Thus, 5 to 7 days of 
HBIG or no HBIG can be used in combination with long-term NAs as prophylaxis, but it 
is important to use NAs with a high barrier to resistance with long-term use.  
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Patients with HIV and HDV coinfection or those with questionable medication adherence 
warrant combination HBIG and NA therapy for prophylaxis (Table 9) because of the 
limited rescue therapies available if HBV recurs. Persistence of circulating HBsAg even 
in low concentrations may increase the risk of HDV infection. Hepatitis B virus and HIV 
coinfected patients frequently have intermittent low-level HBV DNA on NA therapy post–
liver transplant (256), suggesting an important role for HBIG to minimize virological 
breakthrough. For patients maintained on HBIG, subcutaneous and intramuscular routes 
achieve comparable success in preventing HBV recurrence and offer a more convenient 
mode of HBIG administration (257, 258). 
 
For HBsAg-negative liver transplant recipients who receive a HBsAg-negative, anti-HBc–
positive graft, the reported risk of HBV transmission is as high as 75% but varies with the 
HBV immune status of the recipient. Risk is lower for recipients who are anti-HBs-
positive and highest in those without anti-HBc or anti-HBs (259).  Antiviral therapy has 
been shown to be effective in preventing infection and should be started as soon as 
possible postsurgery.  Hepatitis B immune globulin  is not required for prophylaxis (260). 
Though lamivudine has been used widely because of the lower rate of replication risk 
(260), use of antivirals such as entecavir, TDF, or TAF would be predicted to have the 
lowest risk for resistance with long-term use. Tenofovir alafenamide or entecavir are 
preferred in patients who are at higher risk of renal disease (261). 
 
Guidance Statements for Treatment of Liver Transplant Recipients With Hepatitis 
B 
1. All HBsAg-positive patients undergoing liver transplantation should receive 
prophylactic therapy with NAs with or without HBIG posttransplantation regardless of 
HBeAg status or HBV DNA level pretransplant. 
 HBIG monotherapy should not be used. 
 Entecavir, TDF, and TAF are preferred antiviral drugs because of their low rate of 
resistance with long-term use. 
2. An individualized approach to use of HBIG is recommended (Table 9). HBIG for 5 to 
7 days or no HBIG is reasonable in low-risk patients. Combination antiviral therapy 
and HBIG may be the best strategy for those at highest risk of progressive disease 
posttransplantation, such as HDV and HIV coinfected patients. Nonadherent patients 
may benefit from combination prophylaxis with HBIG plus antivirals. 
3. All HBsAg-negative patients who receive HBsAg-negative but anti-HBc–positive 
grafts should receive long-term antiviral therapy to prevent viral reactivation. 
Although lamivudine has been used successfully in this scenario, entecavir, TDF, 
and TAF are preferred choices.  
4. Prophylactic therapy should be lifelong. 
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6I. Nonliver Solid Organ Transplant Recipients 
All patients evaluated for nonliver solid organ transplantation should be tested for 
HBsAg, anti-HBc, and anti-HBs. Patients who are HBsAg-positive should have ALT and 
HBV DNA measurements and undergo staging with biopsy or elastography to determine 
whether advanced fibrosis or cirrhosis is present. Though previously felt to be a 
contraindication, in the current era of antiviral therapies, patients with compensated 
cirrhosis without portal hypertension may be considered for nonhepatic solid organ 
transplantation, with the largest clinical experience in kidney transplantation. Patients 
with decompensated cirrhosis and those with compensated cirrhosis and portal 
hypertension should be considered for combined liver and kidney, heart, and/or lung 
transplantation. 
 
Compared with non–HBV-infected recipients, untreated HBsAg-positive nonliver 
transplant recipients have a higher mortality rate, with liver-related complications as a 
major cause of death (262, 263). Antiviral therapy, however, can mitigate \this mortality 
risk (262, 264, 265). To effectively prevent reactivation, therapy should begin prior to or 
at the time of surgery, regardless of ALT and HBV DNA status, since these parameters 
prior to transplantation have only a limited ability to predict HBV reactivation after 
transplantation. Entecavir, TDF, and TAF are preferred antivirals because of the low rate 
of resistance with long-term use.  
 
The subset of patients who are anti-HBc positive and HBsAg negative are at low risk of 
reactivation posttransplantation, although the risk likely varies with the potency of 
induction and subsequent immunosuppression. While there is insufficient evidence to 
recommend long-term antiviral therapy, a limited duration of prophylaxis for 6 to 12 
months and during periods of intensified immunosuppression may be a reasonable 
strategy. When prophylaxis is stopped, these patients should be monitored using ALT 
levels every 3 months followed by HBV DNA levels if ALT rises. 
 
HBsAg-negative nonliver transplant recipients (kidneys, lungs, heart) who receive an 
organ from an HBsAg-negative, anti-HBc–positive donor have a very low risk of HBV 
acquisition  (259, 266, 267). In a systematic review of studies that included 1385 kidney 
recipients with organs from donors that were HBsAg-negative but anti-HBc positive, 
0.3% became HBsAg positive and 2.3% became anti-HBc positive (267). The presence 
of anti-HBc and/or anti-HBs in the recipients is associated with protection against HBV 
seroconversion (268). However, to reduce this small risk of HBV infection further, 
antiviral therapy should be administered to prevent de novo HBV infection (269). While 
the optimal duration of prophylactic therapy in these nonliver transplant recipients has 
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not been determined, a limited duration (such as 6 to 12 months) may be sufficient. 
Vaccination of the recipients is recommended in those with levels of anti-HBs <10 
mIU/mL.  
 
Guidance Statements for Management of Hepatitis B in Nonliver Solid Organ 
Transplant Recipients 
1. All transplant recipients of extrahepatic organs should be evaluated for HBV infection 
and immunity with HBsAg, anti-HBc, and anti-HBs. Patients without anti-HBs should 
receive hepatitis B vaccination pretransplant. 
2. All HBsAg-positive organ transplant recipients should receive lifelong antiviral 
therapy to prevent or treat reactivation of HBV after transplantation. 
3. Tenofovir (TAF, TDF) and entecavir are preferred antiviral drugs because of the low 
rate of resistance with long-term use. 
4. HBsAg-negative, anti-HBc–positive nonliver recipients should be monitored for 
reactivation without prophylactic therapy. Alternatively, antiviral therapy for the first 6 
to 12 months, the period of maximal immunosuppression, may be considered. 
5. HBsAg-negative, anti-HBc–positive nonliver recipients who received anti-HBc–
positive grafts should be monitored for HBV infection without prophylactic therapy. 
6. Any untreated nonliver recipient undergoing monitoring for reactivation should have 
ALT nd HBV DNA measurements every 3 months for the first year posttransplant 
and after receipt of T cell–depleting therapies, such as antithymocyte globulin. 
 
 
UPDATED RECOMMENDATIONS ON THE TREATMENT OF PATIENTS WITH 
CHRONIC HEPATITIS B 
 
The 2016 HBV treatment guideline recommendations and technical remarks are 
reproduced here, with the new content presented in italics within the Guidance boxes. 
Note that rigorous systematic reviews were used to inform the quality of the evidence 
and the strength (Grading of Recommendations Assessment, Development, and 
Evaluation) of each 2016 Guideline recommendation, but the new Guidance content 
used a comprehensive review of the literature, including studies published after the 
release of the Guideline and expert opinion. 
 
TREATMENT OF PERSONS WITH IMMUNE-ACTIVE DISEASE 
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1A. The AASLD recommends antiviral therapy for adults with immune-
active CHB (HBeAg negative or HBeAg positive) to decrease the risk of 
liver-related complications  
Quality and Certainty of Evidence: Moderate 
Strength of Recommendation: Strong 
 
1B. The AASLD recommends peg-IFN, entecavir, or tenofovir (TDF) as preferred 
initial therapy for adults with immune-active CHB 
Quality and Certainty of Evidence: Low 
Strength of Recommendation: Strong 
 
Guidance: TAF is also a preferred initial therapy for adults with immune-active CHB. 
Consider TAF or entecavir in patients with or at risk for renal dysfunction or bone 
disease. 




1. Immune-active CHB is defined by an elevation of ALT ≥2 the ULN or evidence of 
significant histologic disease plus elevated HBV DNA above 2,000 IU/mL (HBeAg 
negative) or above 20,000 IU/mL (HBeAg positive).  
2. Guidance: The upper limits of normal for ALT in healthy adults is reported to be 29 
to 33 U/L for males and 19 to 25 U/L for females. An upper limit of normal for ALT of 
35 U/L for males and 25 U/L for females is recommended to guide management 
decisions. 
3. There is insufficient evidence for or against use of ALT criterion other than 
ALT ≥2 the ULN. The decision to treat patients with ALT above the upper 
limits of normal but <2 the ULN requires consideration of the severity of liver 
disease (defined by biopsy or noninvasive testing). Therapy is recommended 
for persons with immune-active CHB and cirrhosis if HBV DNA is >2,000 
IU/mL, regardless of ALT level. 
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4. Additional factors included in the decision to treat persons with immune-active 
CHB but ALT <2 the ULN and HBV DNA below thresholds (≤2,000 IU/mL  if 
HBeAg negative or ≤20,000 IU/mL  if HBeAg positive) are as follows: 
• Age: older age (>40 years) is associated with a higher likelihood of significant 
histologic disease. 
• Family history of cirrhosis or HCC. 
• Previous treatment history . 
• Serologic and virologic benefits of peg-IFN occur after treatment 
discontinuation (delayed). 
• Prior NA exposure is a risk for drug resistance. 
• Presence of extrahepatic manifestations: indication for treatment independent of 
liver disease severity. 
• Presence of cirrhosis. 
5. The level of HBV DNA should be compatible with immune-active disease and the 
cutoffs recommended should be viewed as a sufficient but not absolute requirement 
for treatment.   
6. Head-to-head comparisons of antiviral therapies fail to show superiority of one 
therapy over another in achieving risk reduction in liver-related complications. 
However, in recommending peg-IFN, tenofovir, and entecavir as preferred therapies, 
the most important factor considered was the lack resistance with long-term use. 
Patient-specific factors that need to be considered in choosing between peg-IFN, 
entecavir, and tenofovir include the following: 
• Desire for finite therapy (see below). 
• Anticipated tolerability of treatment side effects. 
• Comorbidities: peg-IFN is contraindicated in persons with autoimmune disease, 
uncontrolled psychiatric disease, cytopenia, severe cardiac disease, uncontrolled 
seizures, and decompensated cirrhosis. 
• Previous history of lamivudine resistance (entecavir is not preferred in this 
setting). 
• Family planning: finite therapy with peg-FN prepregnancy or use of an oral 
antiviral agent that is safe in pregnancy (preferably TDF) is best. 
• HBV genotype: A and B genotypes are more likely to achieve HBeAg and HBsAg 
loss with peg-IFN than non-A or non-B genotypes. 
• Medication costs. 
7. Peg-IFN is preferred over nonpegylated forms for simplicity.  
8. For patients treated with peg-IFN, 48 weeks’ duration is used in most studies and is 
preferred. This treatment duration yields HBeAg seroconversion rates of 20% to 31% 
and sustained off-treatment HBV DNA suppression of <2,000 IU/mL in 65% of 
persons who achieve HBeAg to anti-HBe seroconversion. The combination of peg-
IFN and NAs has not yielded higher rates of off-treatment serological or virological 
responses and is not recommended. 
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9. Duration of therapy for NA-based therapy is variable and influenced by 
HBeAg status, duration of HBV DNA suppression, and presence of cirrhosis 
and/or decompensation. All NAs except TAF require dose adjustment in 
persons with creatinine clearance <50 mL/min. 
10. Evaluation for cirrhosis using noninvasive methods or a liver biopsy is useful to guide 
treatment decisions, including duration of therapy.  
11. Treatment with antivirals does not eliminate the risk of HCC, and surveillance for 
HCC should continue in persons who are at risk. 
 
TREATMENT OF IMMUNE-TOLERANT ADULTS WITH CHRONIC HEPATITIS B  
 
2A. The AASLD recommends against antiviral therapy for adults with immune-
tolerant CHB  
Quality and Certainty of Evidence: Moderate 
Strength of Recommendation: Strong 
 
Technical Remarks 
1. Guidance: Immune-tolerant status should be defined by ALT levels, utilizing 35 U/L 
for men and 25 U/L for women as ULN rather than local laboratory ULN.  
 
2B. The AASLD suggests that ALT levels be tested at least every 6 months for 
adults with immune tolerant CHB to monitor for potential transition to immune-
active or immune-inactive CHB 
Quality and Certainty of Evidence: Very Low 
Strength of Recommendation: Conditional 
 
2C. The AASLD suggests antiviral therapy in the select group of adults >40 years 
of age with normal ALT and elevated HBV DNA (1,000,000 IU/mL) and liver biopsy 
specimen showing significant necroinflammation or fibrosis 
Quality and Certainty of Evidence: Very Low 
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Strength of Recommendation: Conditional 
 
Technical Remark: 
1. Moderate-to-severe necroinflammation or fibrosis on a liver biopsy specimen is a 
reason to consider initiation of antiviral therapy if other causes of liver disease are 
excluded. 
 
TREATMENT OF HBEAG-POSITIVE, IMMUNE-ACTIVE PERSONS WITH CHRONIC 
HEPATITIS WHO SEROCONVERT TO ANTI-HBE ON NA THERAPY 
 
3A. The AASLD suggests that HBeAg-positive adults without cirrhosis but with 
CHB who seroconvert to anti-HBe on therapy discontinue NAs after a period of 
treatment consolidation   
Quality and Certainty of Evidence: Very Low 
Strength of Recommendation: Conditional 
 
Technical Remarks 
1. The period of consolidation therapy generally involves treatment of persistently 
normal ALT levels and undetectable serum HBV DNA levels for at least 12 months. 
2. It is not currently known whether a longer duration of consolidation would further 
reduce rates of virological relapse. Thus, an alternative approach is to treat until 
HBsAg loss. 
3. Decisions regarding treatment duration and length of consolidation before 
treatment discontinuation require careful consideration of risks and benefits 
for health outcomes, including the following: (i) risk for virological relapse, 
hepatic decompensation, liver cancer, and death; (ii) burden of continued 
antiviral therapy, financial concerns associated with medication costs and 
long-term monitoring, adherence, and potential for drug resistance with 
treatment interruptions; and (iii) patient and provider preferences. These 
considerations apply for both HBeAg-positive adults without and with cirrhosis 
who seroconvert to anti-HBe on therapy. 
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4. Persons who stop antiviral therapy should be monitored every 3 months for at least 1 
year for recurrent viremia, ALT flares, seroconversion, and clinical decompensation. 
 
3B. The AASLD suggests indefinite antiviral therapy for HBeAg-positive adults 
with cirrhosis with CHB who seroconvert to anti-HBe on NA therapy, based on 
concerns for potential clinical decompensation and death, unless there is a strong 
competing rationale for treatment discontinuation  
Quality and Certainty of Evidence: Very Low 
Strength of Recommendation: Conditional 
 
Technical Remarks 
1. Persons with cirrhosis who stop antiviral therapy should be monitored closely (eg, 
monthly for the first 6 months, then every 3 months) for recurrent viremia, ALT flares, 
seroreversion, and clinical decompensation. 
2. Treatment discontinuation may be considered in persons who have demonstrated 
loss of HBsAg. However, there is currently insufficient evidence to definitively guide 
treatment decisions for such persons. 
 
DURATION OF TREATMENT IN PERSONS WITH HBEAG-NEGATIVE, IMMUNE-ACTIVE 
CHB 
 
4. The AASLD suggests indefinite antiviral therapy for adults with HBeAg-
negative, immune-active CHB unless there is a compelling rationale for treatment 
discontinuation   
Quality and Certainty of Evidence: Low 
Strength of Recommendation: Conditional 
 
Technical Remarks 
1. A decision to discontinue therapy for HBeAg-negative adults without cirrhosis 
requires careful consideration of risks and benefits for health outcomes, including the 
following: (i) risk for virological relapse, hepatic decompensation, liver cancer, and 
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death; (ii) burden of continued antiviral therapy, financial concerns associated with 
medication costs and long-term monitoring, adherence, and potential for drug 
resistance with treatment interruptions; and (iii) patient and provider preferences. 
2. Treatment discontinuation in persons with cirrhosis is not recommended owing to the 
potential for decompensation and death, although data are limited. 
3. Treatment discontinuation may be considered in persons who have demonstrated 
loss of HBsAg. However, there is currently insufficient evidence to definitively guide 
treatment decisions for such persons. 
4. Persons who stop antiviral therapy should be monitored every 3 months for at least 1 
year for recurrent viremia, ALT flares, and clinical decompensation. 
5. Antiviral therapy is not recommended for persons without cirrhosis who are HBeAg 
negative with normal ALT activity and low-level viremia (<2,000 U/mL; “inactive 
chronic hepatitis B”). 
 
RENAL AND BONE DISEASE IN PERSONS ON NA THERAPY 
Quality and Certainty of Evidence: Very Low (Bone); Low (Renal) 
Strength of Recommendation: Conditional 
 
5. The AASLD suggest no preference between entecavir or tenofovir (TDF) 
regarding potential long-term risks of renal and bone complications 
 




1. The existing studies do not show significant differences in renal dysfunction, 
hypophosphatemia, or bone mineral density between HBV-infected persons treated 
with tenofovir (TDF) or entecavir. However, renal events, such as acute renal failure 
or hypophosphatemia, have been reported in TDF-treated persons. 
2. In persons on TDF, renal safety monitoring with serum creatinine, phosphorus, urine 
glucose, and urine protein should be assessed before treatment initiation and 
periodically thereafter (eg, at least annually and more frequently if the patient is at 
high risk for renal dysfunction or has a preexisting renal dysfunction). 
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3. In the absence of other risk factors for osteoporosis or osteomalacia, there is 
insufficient evidence for or against monitoring of bone mineral density in HBV-
infected persons on TDF. 
4. Guidance: In cases of suspected TDF-associated renal dysfunction and/or bone 
disease, TDF should be discontinued and substituted with TAF or entecavir, with 
consideration for any previously known drug resistance. 
5. Dosage of NAs should be adjusted based on renal function and creatinine clearance, 
as recommended by manufacturers. 
 
MANAGEMENT OF PERSONS WITH PERSISTENT LOW-LEVEL VIREMIA ON NA THERAPY 
 
6A. The AASLD suggests that persons with persistent low-level viremia 
(<2,000 IU/mL) on entecavir or tenofovir monotherapy continue 
monotherapy, regardless of ALT 
Quality and Certainty of Evidence: Very Low 
Strength of Recommendation: Conditional 
 
Guidance: Persons on TAF with persistent low-level viremia (<2,000 IU/mL) 
should continue monotherapy, regardless of ALT.  
 
6B. The AASLD suggests 1 of 2 strategies in persons with virological 
breakthrough on entecavir or tenofovir monotherapy: either switch to 
another antiviral monotherapy with a high barrier to resistance or add a 
second antiviral drug that lacks cross-resistance (Table 8)  
Quality and Certainty of Evidence: Very Low 
Strength of Recommendation: Conditional 
 
Technical Remarks 
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1. Counseling patients about medication adherence is important, especially in those 
with persistent viremia on antiviral therapy. 
2. Persistent viremia has traditionally been defined as detectable HBV DNA after 48 
weeks of treatment. This time point was defined by outcomes of virological response 
in clinical trials and reflects an era of antiviral therapy with drugs of lower antiviral 
potency and higher rates of resistance. 
Guidance: With the current preferred therapies of entecavir, TDF, and TAF, persistent 
viremia is defined as a plateau in the decline of HBV DNA and/or failure to achieve an 
undetectable HBV DNA level after 96 weeks of therapy. There is insufficient comparative 
evidence to advocate for adding a second drug or switching to another drug in lieu of 
continuing monotherapy.  
Resistance testing in this setting may not be technically possible if the viral level is 
low. Medical providers should ensure patient adherence to therapy. 
3. Viral breakthrough is defined by an increase in HBV DNA by >1 log compared to 
nadir or an HBV DNA level of 100 IU/mL or higher in persons on NA therapy with a 
previously undetectable level (<10 IU/mL). Confirmatory testing should be obtained 
before making a therapy change. Resistance testing may assist with decisions 
regarding subsequent therapy. A confirmed virological breakthrough constitutes a 
rationale for switching to another antiviral monotherapy with a high genetic barrier to 
resistance or adding a second antiviral with a complementary resistance profile 
(Table 8).  
Guidance: 
a) For patients on entecavir with virological breakthrough, change to or add TDF 
or TAF. 
b) For patients on TDF or TAF with virological breakthrough, changing to or 
adding entecavir is preferred, depending upon prior NA experience.  
There is insufficient long-term comparative evidence to advocate one 
appr ach over another. Based upon virological principles, the risk of viral 
resistance is predicted to be lower with combination antiviral therapy 
compared with monotherapy. Comparative evidence with follow-up to 5 years 
suggests monotherapy achieves rates of HBV DNA suppression comparable 
to those of combination therapy when antivirals such as tenofovir are used 
(231, 232). 
4. Although the optimal frequency of HBV DNA monitoring has not been fully 
evaluated, monitoring of HBV DNA levels every 3 months until HBV DNA is 
undetectable and then every 3 to 6 months thereafter allows for detection of 
persistent viremia and virological breakthrough. 
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5. For persons on treatment with NAs other than tenofovir or entecavir, viral 
breakthrough warrants a switch to another antiviral monotherapy with a high genetic 
barrier to resistance or the addition of a second antiviral with a complementary 
resistance profile (Table 8). 
Guidance: 
a) For patients on the nonpreferred antivirals lamivudine or telbivudine who 
develop virologic breakthrough, change to or add TAF or TDF. 
b) For patients on the nonpreferred antiviral adefovir who develop virologic 
breakthrough, change to or add entecavir, TAF, TDF. 
 
MANAGEMENT OF ADULTS WITH CIRRHOSIS AND LOW-LEVEL VIREMIA 
 
7A. The AASLD suggests that adults with compensated cirrhosis and low level 
viremia (<2,000 IU/mL) be treated with antiviral therapy to reduce the risk of 
decompensation, regardless of ALT level. 
Quality and Certainty of Evidence: Very Low 
Strength of Recommendation: Conditional 
 
Technical Remarks 
1. Tenofovir and entecavir are preferred because of their potency and minimal 
risk of resistance, decompensation, and serious side effects. Antivirals with a 
low genetic barrier to resistance are not recommended because the 
emergence of resistance can lead to decompensation. 
Guidance: TAF should be considered an additional preferred antiviral drug. 
2. Peg-IFN is not contraindicated in persons with compensated cirrhosis, but 
NAs are safer. 
3. If treatment is not offered to persons with compensated cirrhosis and low 
levels of viremia, they must be closely monitored (every 3–6 months) for a 
rise in HBV DNA and/or clinical decompensation. Treatment should be 
initiated if either occurs. 
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4. The ALT level in these persons is typically normal or less than 2 times the ULN. 
Higher ALT levels (>2 times the ULN) warrant consideration of other causes for ALT 
elevation and, if none are found, they are a stronger indication for antiviral therapy. 
5. Current evidence does not provide an optimal length of treatment. If therapy were 
discontinued, close monitoring (at least every 3 months for at least 1 year) would 
allow for early detection of viral rebound that could lead to decompensation. 
6. Persons with compensated cirrhosis and high HBV DNA level (>2,000 U/mL) are 
treated per recommendations for HBeAg-positive and HBeAg-negative immune-
active CHB (recommendation 1A and 1B). 
7. Treatment with antivirals does not eliminate the risk of HCC and surveillance for 
HCC should continue. 
 
7B. The AASLD recommends that HBsAg-positive adults with 
decompensated cirrhosis be treated with antiviral therapy indefinitely 
regardless of HBV DNA level, HBeAg status, or ALT level to decrease risk 
of worsening liver-related complications 
Quality and Certainty of Evidence: Moderate 
Strength of Recommendation: Strong 
 
Technical Remarks 
1. Entecavir and tenofovir (TDF) are recommended drugs.  
Guidance: TAF has not been studied in patients with decompensated cirrhosis, 
thus limiting recommendations to use TAF in these patients. However, TAF or 
entecavir should be considered in patients with decompensated cirrhosis who 
have renal dysfunction and/or bone disease.  
2. Peg-IFN is contraindicated in patients with decompensated cirrhosis because 
of safety concerns. 
3. Concurrent consideration for liver transplantation is indicated in eligible persons. 
4. Patients should be monitored closely for the development of adverse effects 
of antiviral therapy, such as renal insufficiency and lactic acidosis. 
5. Treatment with antivirals does not eliminate the risk of HCC and surveillance for 
HCC should continue. 
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MANAGEMENT OF CHRONIC HEPATITIS B IN PREGNANCY 
 
8A. The AASLD suggests antiviral therapy to reduce the risk of perinatal 
transmission of HBV in HBsAg-positive pregnant women with an HBV DNA 
level >200,000 IU/mL 
Quality and Certainty of Evidence: Low 
Strength of Recommendation: Conditional 
 
Technical Remarks 
1. The infants of all HBsAg-positive women should receive immunoprophylaxis (HBV 
vaccination with or without hepatitis B immunoglobulin, per World Heath 
Organization and Centers for Disease Control and Prevention recommendations). 
2. The only antivirals studied in pregnant women are lamivudine, telbivudine, and TDF.  
Of these 3 options, TDF is preferred to minimize the risk of emergence of viral 
resistance during treatment. Interim studies show high efficacy of TDF in preventing 
mother-to-child transmission. 
Guidance: TAF has not been studied in pregnant women and no data have been 
reported to the antiretroviral registry regarding the safety of TAF in pregnancy. Thus, 
there are insufficient data to recommend use of TAF in pregnancy. 
3. Antiviral therapy was started at 28 to 32 weeks of gestation in most of the studies. 
4. Antiviral therapy was discontinued at birth to 3 months postpartum in most of the 
studies. With discontinuation of treatment, women should be monitored for ALT 
flares every 3 months for 6 months. 
5. There are limited data on the level of HBV DNA for which antiviral therapy is routinely 
recommended. The level of >200,000 IU/mL is a conservative recommendation. 
6. For pregnant women with immune-active hepatitis, treatment should be based on 
recommendations for nonpregnant women. 
7. Breastfeeding is not contraindicated. These antivirals are minimally excreted in 
breast milk and are unlikely to cause significant toxicity. The unknown risk of low-
level exposure to the infant should be discussed with mothers. 
8. There are insufficient long-term safety data in infants born to mothers who took 
antiviral agents during pregnancy and while breastfeeding. 
9. C-section is not indicated owing to insufficient data to support its benefit. 
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8B. The AASLD recommends against the use of antiviral therapy to reduce the risk 
of perinatal transmission of HBV in HBsAg-positive pregnant women with an HBV 
DNA level ≤200,000 IU/mL  
Quality and Certainty of Evidence: Low 
Strength of Recommendation: Strong 
 
TREATMENT OF CHB IN CHILDREN 
 
9A. The AASLD suggests antiviral therapy in HBeAg-positive children (ages 2 to 
<18 years) with both elevated ALT and measurable HBV DNA levels, with the goal 
of achieving sustained HBeAg seroconversion  
Quality and Certainty of Evidence: Moderate 
Strength of Recommendation: Conditional 
 
Technical Remarks 
1. Most studies required ALT elevation (>1.3 times the ULN) for at least 6 months with 
HBV DNA elevations for inclusion. Given that HBV DNA levels are typically very high 
during childhood (>106 IU/mL), there is no basis for a recommendation for a lower 
limit value with respect to treatment. However, if a level <104 IU/mL is observed, 
therapy might be deferred until other causes of liver disease and spontaneous 
HBeAg seroconversion are excluded. 
Guidance: The upper limits of normal for ALT in healthy children are not firmly 
established and appear to vary not only by sex but age, pubertal stage, and BMI (270).  
Reports suggest cutoff values from 22 to 31 U/L for girls and 25 to 38 U/L for boys after 
infancy (271–273), although not all studies carefully excluded overweight children. For 
CHB purposes and for consistency with recommendations in adults, an upper limit of 
normal for ALT of 35 U/L for males and 25 U/L for females is suggested to guide 
management decisions. 
2. IFN-α-2b is approved for children 1 year of age and older, whereas lamivudine and 
entecavir are approved for children 2 years of age and older. Peg-IFN-α-2a (180 
mcg/1.73 m2 body surface area to maximum 180 mcg once weekly) is not approved 
for children with CHB but is approved for treatment of chronic hepatitis C for children 
Page 45 of 87
Hepatology
Hepatology









t HBV Guidance 2018  
46 
Submitted for publication on January 11, 2018 
5 years of age or older. Providers may consider using this drug for children with 
chronic HBV. 
3. Treatment with entecavir is associated with a lower risk of viral resistance compared 
with lamivudine. 
4. TDF is approved for children 12 years of age and older. 
Guidance: TAF has not been studied in children. Thus, there are insufficient data to 
recommend use of TAF in children 12 years of age and older. 
5. Duration of treatment with IFN-α-2b is 24 weeks. 
6. The duration of treatment with oral antivirals that has been studied is 1 to 4 years. It 
may be prudent to use HBeAg seroconversion as a therapeutic endpoint when oral 
antivirals are used and continue treatment for an additional 12 months of 
consolidation, as recommended in adults. It is currently unknown whether a longer 
duration of consolidation would reduce rates of virological relapse. 
7. Children who stop antiviral therapy should be monitored every 3 months for at least 1 
year for recurrent viremia, ALT flares, and clinical decompensation. 
 
9B. The AASLD recommends against the use of antiviral therapy in HBeAg-
positive children (ages 2 to <18 years) with persistently normal ALT, regardless of 
HBV DNA level. 
Quality and Certainty of Evidence: Very Low 
Strength of Recommendation: Strong 
 
Technical Remarks 
1. Normal ALT in children has not been clearly defined. 
Guidance: An upper limit of normal for ALT of 35 U/L for males and 25 U/L for females 
is suggested to guide management decisions. 
2. Although some studies of IFN included children with normal ALT values, studies of 
oral antiviral agents did not include children with normal ALT values. 
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Abbreviations: AFP, alpha-fetoprotein; ALT, alanine transaminase; anti-HBc, antibody to 
hepatitis B core antigen; anti-HBe, antibody to hepatitis B e antigen; anti-HBs, antibody 
to hepatitis B surface antigen; ARVT, antiretroviral therapy; CHB, chronic hepatitis B; 
DAA, direct-acting antiviral; HBeAg, hepatitis B e antigen; HBIG, hepatitis B immune 
globulin; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular 
carcinoma; HCV, hepatitis C virus; HDV, hepatitis D virus;  HIV, human 
immunodeficiency virus; IFN, interferon; IFN-α, interferon-alfa; NA, nucleos(t)ide 
analogue; peg-IFN, peginterferon; peg-IFN-α, pegylated interferon-alfa; qHBsAg, 
quantitative hepatitis B surface antigen; TAF tenofovir alafenamide; TDF, tenofovir 
disoproxil fumarate; ULN, upper limits of normal; US, ultrasonography 
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C Flu-like symptoms, 
fatigue, mood 
disturbances, cytopenia, 
autoimmune disorders in 
adults, anorexia and 
weight loss in children 
Complete blood count (monthly to 
every 3 months) 
TSH (every 3 months) 
Clinical monitoring for 
autoimmune, ischemic, 
neuropsychiatric, and infectious 
complications 









kg: 0.5 mg 
daily5 
C Lactic acidosis  
(decompensated 
cirrhosis only) 
Lactic acid levels if there is clinical 
concern 
 











Creatinine clearance at baseline 
If at risk for renal impairment, 
creatinine clearance, serum 
phosphate, urine glucose and 
protein at least annually 
Consider bone density study at 
baseline and during treatment in 
patients with history of fracture or 


















risks for osteopenia 
Lactic acid levels if there is clinical 
concern  






-- There are 
insufficient human 
data on use 
during pregnancy 
to inform a drug-
associated risk of 
birth defects and 
miscarriage 
Lactic acidosis Lactic acid levels if clinical concern 
Assess serum creatinine, serum 
phosphorus, creatinine clearance, 
urine glucose, and urine protein 
prior to initiating and during 
therapy in all patients as clinically 
appropriate 
 
Test for HIV prior to treatment 
initiation  
Non-Preferred 










Amylase if symptoms are present 
Lactic acid levels if there is clinical 
concern 
Test for HIV prior to treatment 
initiation 
Adefovir 10 mg 
daily 




Creatinine clearance at baseline 
If at risk for renal impairment, 
creatinine clearance, serum 
phosphate, urine glucose, and 
urine protein at least annually 
Consider bone density study at 


















baseline and during treatment in 
patients with history of fracture or 
risks for osteopenia 
Lactic acid levels if clinical concern 
Telbivudine 600 mg 
daily 
-- B Creatine kinase 
elevations and myopathy 
Peripheral neuropathy 
Lactic acidosis 
Creatine kinase if symptoms are 
present 
Clinical evaluation if symptoms are 
present 
Lactic acid levels if there is clinical 
concern 
1 Dose adjustments are needed in patients with renal dysfunction. 
2 In 2015, the US Food and Drug Administration replaced the pregnancy risk designation by letters A, B, C, D, and X with 
more specific language on pregnancy and lactation. This new labeling is being phased in gradually, and to date only TAF 
includes these additional data.  
3 Per package insert. 
4 Peg-IFN-α-2a is not approved for children with chronic hepatitis B but is approved for treatment of chronic hepatitis C. 
Providers may consider using this drug for children with chronic HBV. The duration of treatment indicated in adults is 48 
weeks. 
5 Entecavir dose is 1 mg daily if the patient is lamivudine experienced or if they have decompensated cirrhosis. 
  


















Table 2:  Efficacy of Approved First-Line Antiviral Therapies in Adults with Treatment-Naïve Chronic Hepatitis B 
and Immune-Active Disease (Not Head-to-Head Comparisons) 
 






% HBV DNA suppression (cutoff to 
define HBV DNA suppression)4 
30–42 (<2000–
40,000 IU/mL) 
8-14 (<80 IU/mL) 
61 (<50–60 
IU/mL) 
76 (<60 IU/mL) 73 (<29 IU/mL) 
% HBeAg loss 32–36    22–25 -- 22 
% HBeAg seroconversion 29–36  21–22 21 18 
% Normalization ALT 34–52    68–81 68 -- 
% HBsAg loss 
2–7   
11 (at 3 years 
posttreatment) 
2–3 
4-5 (2 years) 
3 
8 (3 years) 
1 
(2 years) 






% HBV DNA suppression (cutoff to 
define HBV DNA suppression)5 
43 (<4000 IU/mL) 
19 (<80 IU/mL) 
90–91 (<50–60 
IU/mL) 
93 (<60 U/mL) 90 (<29 IU/mL) 
% Normalization ALT6 59 78–88 76 81 
% HBsAg loss 
4 
6 (at 3 years 
posttreatment) 
0–1 0 <1 
References: (6–16) 
1 Assessed 6 months after completion of 12 months of therapy 
2 Assessed after 3 years of continuous therapy 
3 Assessed after 2 years of continuous therapy 


















4 HBV DNA <2000-40,000 IU/mL for peginterferon; <60 IU/mL for entecavir and tenofovir disoproxil fumarate; <29 IU/mL 
for tenofovir alafenamide 
5 HBV DNA <20,000 IU/mL for peginterferon; <60 IU/mL for entecavir and tenofovir disoproxil fumarate; <29 IU/mL for 
tenofovir alafenamide 
6 ALT normalization defined by laboratory normal rather than ≤35 and ≤25 U/L for males and females 
 
 


















Table 3: Groups at High Risk for HBV Infection Who Should Be Screened 
 
 Persons born in regions of high or intermediate HBV endemicity (HBsAg prevalence of ≥2%) 
Africa 
North, Southeast, East Asia 










All countries except Australia and New Zealand 
All countries except Cyprus and Israel 
All countries except Hungary 
Malta, Spain, and indigenous populations of Greenland 
Alaskan natives and indigenous populations of Northern Canada 
Guatemala and Honduras 
Ecuador, Guyana, Suriname, Venezuela, and Amazonian areas 
Antigua-Barbuda, Dominica, Grenada, Haiti, Jamaica, Saint Kitts and Nevis, 
Saint Lucia, and Turks and Caicos Islands 
 US-born persons not vaccinated as an infant whose parents were born in regions with high HBV endemicity (≥8%)* 
 Persons who have ever injected drugs* 
 Men who have sex with men* 
 Persons needing immunosuppressive therapy, including chemotherapy, immunosuppression related to organ transplantation, 
and immunosuppression for rheumatologic or gastroenterologic disorders 
 Individuals with elevated ALT or AST of unknown etiology* 
 Donors of blood, plasma, organs, tissues, or semen 
 Persons with end-stage renal disease, including predialysis, hemodialysis, peritoneal dialysis, and home dialysis patients* 
 All pregnant women  
 Infants born to HBsAg-positive mothers* 
 Persons with chronic liver disease, eg, HCV* 
 Persons with HIV* 
 Household, needle-sharing and sexual contacts of HBsAg-positive persons* 
 Persons who are not in a long-term, mutually monogamous relationship (eg >1 sex partner during the previous 6 months)*  
 Persons seeking evaluation or treatment for a sexually transmitted disease* 
 Health care and public safety workers at risk for occupational exposure to blood or blood-contaminated body fluids* 


















 Residents and staff of facilities for developmentally disabled persons* 
 Travelers to countries with intermediate or high prevalence of HBV infection* 
 Persons who are the source of blood or body fluid exposures that might require post-exposure prophylaxis 
 Inmates of correctional facilities* 
 Unvaccinated persons with diabetes who are aged 19 through 59 years (discretion of clinician for unvaccinated adults with 
diabetes who are aged ≥60 years)* 
* Those who are seronegative should receive hepatitis B vaccine 
Sources: (23, 35, 36) 
 
  


















Table 4: Interpretation of Screening Tests for HBV Infection 
 
Screening Test Results Interpretation Management Vaccinate? 
HBsAg  Anti-HBc Anti-HBs 
+ + - Chronic  hepatitis B 
Additional testing and 
management needed 
No 
- + + 
Prior HBV infection, 
resolved 
No further management 
unless immunocompromised 




- + - 
Prior HBV infection, 
resolved or false-positive  
HBV DNA testing if 
immunocompromised patient 
Yes, if not from area of 
intermediate or high 
endemicity 
- - + Immune  No further testing No 
- - - 
Uninfected and not 
immune 
No further testing Yes 
 
  


















Table 5: Recommendations for Infected Persons Regarding Prevention of Transmission of HBV to Others 
 
Persons Who Are HBsAg Positive Should: 
 Have household and sexual contacts vaccinated 
 Use barrier protection during sexual intercourse if partner is not vaccinated or is not naturally immune 
 Not share toothbrushes or razors 
 Not share injection equipment 
 Not share glucose testing equipment 
 Cover open cuts and scratches 
 Clean blood spills with bleach solution 
 Not donate blood, organs, or sperms 
Children and Adults Who Are HBsAg Positive: 
 Can participate in all activities, including contact sports 
 Should not be excluded from daycare or school participation and should not be isolated from other children 






















Table 6: Diagnostic Criteria and Definitions for Chronic Hepatitis B 
 
Chronic Hepatitis B (CHB)  
1. HBsAg present for ≥6 months 
2. Serum HBV DNA varies from undetectable to several billion IU/mL 
3. Subdivided into HBeAg positive and negative. HBV DNA levels are typically >20,000 IU/mL in HBeAg-positive CHB, 
and  lower values (2000–20,000 IU/mL) are often seen in HBeAg-negative CHB 
3. Normal or elevated ALT and/or AST levels 
4. Liver biopsy results showing chronic hepatitis with variable necroinflammation and/or fibrosis 
 
Immune-Tolerant CHB 
1. HBsAg present for ≥6 months 
2. HBeAg positive 
3. HBV DNA levels are very high (typically >1 million IU/mL) 
4. Normal or minimally elevated ALT and/or AST 
4. Liver biopsy or noninvasive test results  showing no fibrosis and minimal inflammation 
 
Immune-Active CHB 
1. HBsAg present for ≥6 months 
2. Serum HBV DNA >20,000 IU/mL in HBeAg-positive CHB and >2000 IU/mL in HBeAg-negative CHB 
3. Intermittently or persistently elevated ALT and/or AST levels 
4. Liver biopsy or noninvasive test results showing chronic hepatitis with moderate or severe necroinflammation and 
with or without fibrosis 
 
Inactive CHB 
1. HBsAg  present for ≥6 months 
2. HBeAg negative, anti-HBe positive 
3. Serum HBV DNA <2000 IU/mL 
4. Persistently normal ALT and/or AST levels 
5. Liver biopsy confirms absence of significant necroinflammation. Biopsy or noninvasive testing show variable levels of 
fibrosis 



















Other Definitions  
 HBV reactivation: loss of HBV immune control in HBsAg-positive, anti-HBc–positive or HBsAg-negative, anti-HBc–positive 
patients receiving immunosuppressive therapy for a concomitant medical condition; a rise in HBV DNA compared to baseline (or 
an absolute level of HBV DNA when a baseline is unavailable); and reverse seroconversion (seroreversion) from HBsAg-negative 
to HBsAg-positive for HBsAg-negative, anti-HBc–positive patients 
 Hepatitis flare: ALT increase ≥3 times baseline and >100 U/L 
 HBV-associated hepatitis: HBV reactivation and hepatitis flare  
 HBeAg clearance: loss of HBeAg in a person who was previously HBeAg positive 
 HBeAg seroconversion: loss of HBeAg and detection of anti-HBe in a person who was previously HBeAg positive and anti-HBe 
negative 
 HBeAg seroreversion: reappearance of HBeAg in a person who was previously HBeAg negative 
 Resolved CHB: sustained loss of HBsAg in person who was previously HBsAg positive, with undetectable HBV DNA levels and 
absence of clinical or histologic evidence of active viral infection  
 Virologic breakthrough:  >1 log10 (10-fold) increase in serum HBV DNA from nadir during treatment in a patient who had an initial 






















Table 7: HBsAg-Positive Persons at High Risk of HDV Infection Who Should Be Screened 
 
 








West Africa, horn of Africa 
Central and Northern Asia, Vietnam, Mongolia, Pakistan, Japan, Taiwan,  
Kiribati, Nauru 
All countries  




 Persons who have ever injected drugs 
 Men who have sex with men 
 Individuals infected with HCV or HIV 
 Persons with multiple sexual partners or any history of sexually transmitted disease 
 Individuals with elevated ALT or AST with low or undetectable HBV DNA 
 
* This list is incomplete, as many countries do not report HDV rates. 































Add Strategy:  




(TDF or TAF) 
 
Continue lamivudine; add tenofovir (TDF or 
TAF) 




(TDF or TAF) 
 







(TDF or TAF) 





(TDF or TAF) 
Continue entecavir; add tenofovir (TDF or 
TAF) 










Combined tenofovir (TDF or TAF) 
and entecavir* 
 
* Efficacy appears similar with switching to an antiviral with high genetic barrier to resistance and without cross-resistance 






















Table 9: Factors Influencing the Choice of Prophylaxis of HBsAg-Positive Liver Transplant Recipients 
 
 Long-term HBIG Plus Indefinite 
NAs 











Presence of drug resistance or 




No drug-resistant variants 
Undetectable to low (<100 IU/mL) HBV 
DNA at time of LT 
Absence of HIV and HDV coinfection 
Other 
Access to HBIG 
Lack access to entecavir or 
tenofovir (TDF or TAF) 
Access to entecavir or tenofovir (TDF or 
TAF) 
 
NA: nucleos(t)ide analogues; HBIG: hepatitis B immune globulin; TDF: Tenofovir dipovoxil fumarate; TAF: tenofovir 
alafenamide; LT: liver transplant; HIV: human immunodeficiency virus; HDV: hepatitis D virus  
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